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Summary 
Magnetic resonance imaging of the spinal cord is a valuable part of the diagnostic work-up in patients with 
multiple sclerosis and other neurological disorders. Currently, mainly signal intensity changes within the cord 
in MR-images are considered in the clinical management of disorders of the central nervous system. However, 
cross-sectional or longitudinal measurements of spinal cord volume may deliver additional valuable 
information. Hence, the overall goal of this doctoral thesis was twofold: i) to clinically validate methods for 
quantification of spinal cord volume and spinal cord compartments, which are suitable for longitudinal 
assessment of large patient cohorts and clinical practice and ii) to evaluate spinal cord volume as a potential 
valuable biomarker and provide new insights into the role of spinal cord damage in multiple sclerosis. 
The first part focuses on the validation of quantification methods for spinal cord volume and includes two 
projects. While several MRI-based approaches of semi- and fully automatic techniques for volumetric spinal 
cord measurements have been proposed, up to now no gold standard exists and only a few methods have been 
validated and/or evaluated on patient follow-up scans to demonstrate their applicability in longitudinal 
settings. One of the latter segmentation methods was recently developed in-house and showed excellent 
reliability for cervical cord segmentation (Cordial, the cord image analyzer). In a first project, we extended its 
applicability to the lumbar cord, since no other software has been tested so far within this anatomical region 
of interest. On a well-selected dataset of 10 healthy controls (scanned in a scan-rescan fashion) we were able 
to show that - even within this technically challenging region - this segmentation algorithm provides excellent 
inter- and intra-session reproducibility showing high potential for application in longitudinal trials 
(Manuscript 1, published in European Radiology). In a second project, we aimed at obtaining volumetric 
information on particular compartments of the spinal cord such as the cord grey and white matter, since recent 
studies in multiple sclerosis provided evidence that measuring spinal cord grey matter volume changes may 
be a better biomarker for disease progression than quantifying cord white matter pathology or even volumetric 
brain measures. We therefore implemented a novel imaging approach, the averaged magnetization inversion 
recovery acquisitions sequence, for better grey and white matter visualization within the cord and scanned 24 
healthy controls in a scan-rescan fashion. Further we applied an innovative fully automatic variational 
segmentation algorithm with a shape prior modified for 3D data with a slice similarity prior to segment the 
spinal cord grey and white matter. This pipeline allowed for highly accurate and reproducible grey and white 
matter segmentation within the cord. In view of its features, our automatic segmentation method seems 
promising for further application in both crossectional and longitudinal and in large multi-center studies 
(Manuscript 2, accepted American Journal of Neuroradiology). 
The second goal of this thesis was the clinical application of the above-mentioned methods for the evaluation 
of spinal cord volume changes as a potential biomarker in multiple sclerosis patients. For this purpose, we 
quantified spinal cord volume change in a large cohort of 243 multiple sclerosis patients, followed over a 
period of 6 years with annual clinical and MRI examinations. Spinal cord volume proved to be a strong 
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predictor of physical disability and disease progression, indicating that it may be a suitable marker for 
monitoring disease activity and severity in all disease types but especially in progressive multiple sclerosis. 
Spinal cord volume also proved to be the only MRI metric to strongly explain the clinical progression over 
time as opposed to brain atrophy and lesion measures (Manuscript 3+4 published in Neurology and Multiple 
Sclerosis Journal respectively). 
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1. Introduction 
 
1.1. Magnetic Resonance Imaging of the Spinal Cord: Current State and 
Challenges 
Magnetic resonance imaging (MRI) is the method of choice in investigating disorders of the spinal cord (SC) 
in a fairly quick and non-invasive fashion. Based on the magnetic properties of the hydrogen atoms, abundant 
in the human body in fat and water, various MRI contrasts may be generated and deliver anatomical detail, 
information on structural composition and tissue function1–3. For that purpose, a number of different MR-
sequences and contrasts are used including relaxation time-weighted (T1, T2, T2*), proton-density weighted, 
magnetization prepared rapid gradient echo, fast-spin echo, phase-sensitive and short tau inversion recovery 
techniques 4. 
However, in contrast to brain MRI, the environment of the SC presents additional challenges for MRI methods 
1–3,5. Greatest challenge is the inhomogeneous magnetic field across the SC due to the different magnetic 
properties of the surrounding tissues, e.g. cerebrospinal fluid (CSF), fat, vertebral bones, and air-tissue 
interfaces. This may lead to image distortions and a loss of spatial resolution. Further, the SC is a fairly thin 
and curved structure with a maximal antero-posterior diameter of 8.3 ± 1.6mm at the C1 level and maximal 
latero-lateral diameter of 13.3 ± 2.2mm at the C5 level 6–13, which results in partial volume effects (a mix of 
tissues with different relaxation properties in one voxel) at the SC/CSF borders 1–3,5. Another challenge is the 
cord’s physiological movement in the spinal canal as a result of cardiac-induced pulsatile CSF motion, 
respiratory motion, and swallowing resulting in MRI motion artifacts 14–16. Contact of the SC with some point 
of the osseous canal, which partially eliminates contrast between the SC and its surroundings further hampers 
assessment. Furthermore, osteophytes of the spinal column can cause focal changes in CSF flow dynamics 
within the spinal canal causing so called CSF flow artifacts. Finally, Gibbs truncation artifacts are very 
common in SC MRI resulting in high signal in the center and dark edges of the SC. 
Another limitation is the currently insufficient contrast between SC grey matter (GM), white matter (WM) 
and CSF on conventional SC MRI. Only recently, advanced MRI sequences were able to overcome those 
obstacles providing images with sufficient signal- and contrast-to-noise ratios between SC compartments in 3 
Tesla MRI machines. First attempts utilized a 3D-fast field echo sequence (T2w) 17, a 3D multiple echo data 
image combination sequence (T2*w) 18, a 2D phase sensitive inversion recovery sequence (T1w) 19 and most 
recently a modified look-locker inversion recovery sequence with single-shot balanced steady state free 
precession (T2w) 20 as well as an averaged magnetization inversion recovery acquisitions (AMIRA) sequence 
(T2w) 21 (Figure 1). In particular, AMIRA acquires eight images of remarkable tissue contrast variation 
between SC GM and WM CSF in clinically feasible acquisition times. Averaging the first images enhances 
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the contrast-to-noise ratio between GM and WM, whereas averaging the last images considerably improves 
the WM/CSF contrast-to-noise ratio. 
Figure 1. SC GM and WM contrast acquired with: fast field echo (left) 17, phase sensitive inversion recovery 
(middle) 19, averaged magnetization inversion recovery acquisitions (right) 21 sequences. 
 
Despite anatomical and methodological challenges, SC MRI is essential in clinical routine and can be 
generally assessed in two ways: qualitatively or quantitatively. Qualitative SC MRI assessment involves 
neuroradiologists searching for MRI signal intensity changes within the SC in order to distinguish normal SC 
tissue from focal intramedullar pathology such as demyelination, edema, or inflammation e.g. in multiple 
sclerosis (MS) lesions (Figure 2). This is currently the sole use of SC MRI in clinical settings. However, some 
of the disorders affecting the SC do not present with focal abnormalities in the sense of hypo- or hyperintense 
lesions on MRI but are rather characterized by neurodegeneration of various aetiologies leading to neuronal 
loss and shrinkage, Wallerian degeneration and axonal loss (e.g. spinal muscular atrophy, amyotrophic lateral 
sclerosis). Others do manifest with MRI intensity changes indicating inflammatory and demyelinating lesions, 
which -however- do not represent the entire underlying SC pathology and often do not serve as reliable 
biomarkers (e.g. MS, human-T-cell lymphotropic virus type-1 (HTLV-1) associated myelopathy). 
Nevertheless, the aftermath of those neurodegenerative and demyelinating processes is tissue shrinkage and 
can be assessed in vivo on MRI as SC volume loss. Hence, cross-sectional or longitudinal quantitative 
measurements of SC volume and/or cross-sectional area indirectly deliver additional valuable information 
regarding mechanisms of neuropathology, that cannot be appreciated with the naked eye in qualitative 
assessments of SC MRI. Nonetheless, this is not part of clinical routine for the time being. 
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Figure 2. Multiple sclerosis SC lesions in sagittal images acquired with: a) Proton-density-weighted, b) T2-weighted, 
c) phase-sensitive inversion recovery and d) short tau inversion recovery imaging 5. 
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1.2. Spinal Cord Volume Quantification 
 
1.2.1. Image Segmentation  
Generally speaking, image segmentation is the process of dividing an image into different parts, aiming to 
define specific regions, whose boundaries separate image parts that display distinct features. This is especially 
interesting in the medical field in order to be able to quantify certain image properties for clinical or scientific 
goals. In general, this can be performed in two ways: manually or computer-based. 
Manual image segmentations are performed by human observers, who may outline the objects or regions of 
interest intuitively or after completing some specific training. However, this approach is associated with 2 
major limitations. The first one is that the task requires a considerable amount of time depending on the region 
of interest. This especially applies to medical imaging where the generation of swift diagnostic answers in a 
high number of patients with the least number of medical staff possible involved is necessary for logistic 
reasons. The second limitation is much more important, since it concerns the more systematic problem of 
reproducibility, which is essential in every diagnostic approach to be applied in scientific studies and/or 
clinical routine. It is very likely that two observers (a.k.a. raters) manually segmenting the same image will 
not produce exactly the same result, thus the inter-observer (or inter-rater) reproducibility is limited. 
Moreover, even the same observer will most probably create different segmentations should it be required to 
segment an image twice, thus the intra-observer (or intra-rater) reliability is limited. Adding other limitations 
related to medical images (such as MR-imaging) to the variability of measurements extracted out of manual 
segmentations can result in a considerable variation. This is important when taking into consideration that 
many image-extracted measurements are for example meant to be deployed for the purpose of patient 
monitoring in a longitudinal fashion, where small changes occur over time.  
In the light of the above-mentioned limitations of manual image segmentations, computer-based image 
segmentation could release the medical staff from a highly time-consuming task and increase the 
reproducibility of those measurements. Computer-based image segmentations are, however, confronted with 
a new series of challenges. As a result, a plethora of computer-based image segmentation techniques have 
been proposed. In summary, those methods can be divided in 3 categories: a) basic or ad hoc 22, b) machine 
learning 23 and c) energy-based techniques 24–26. A complete review and analysis of those techniques is beyond 
the scope of this thesis. 
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1.2.2. SC Segmentation  
Much like any other medical image, manual segmentation of SC MRI is a very time-consuming and rater-
dependent task. Implementing image segmentation techniques to quantify the SC volume and cross-sectional 
areas have been introduced since 1996 27. Despite that, computer-based SC segmentation remains demanding 
in part due to limitations hampering SC MR-imaging (as mentioned in 1.1). A big number of semi- and fully 
automatic techniques have been proposed 28. The most important include active contours of surfaces 29–32, 
level sets 33, partial volume modeling 34, gradient vector flow 35, atlas-based approaches 36,37 , and tubular 
deformable models 38 with variable required user interaction from manual identification of the SC centerline 
31 to the identification of multiple 30 or single 29,37 anatomical landmarks, with completely automated 
approaches presented only recently (Figure 3) 39. In the past, SC atrophy was usually determined by assessing 
the cross-sectional area of the cervical cord, usually at the C2/C3 level, which has been shown to correlate 
with clinical measures, although reproducibility was limited and depending on data quality as well as 
repositioning 27,40,41. However, until now only a few of those methods have been validated and/or evaluated 
on patient follow-up data to demonstrate the applicability in longitudinal trial settings with up to two years 
follow up time 27,31,39,42–45. Most recently, a new method (Cordial, the cord image analyzer) was developed 
with longitudinal studies in mind, which provides measurements of SC sections with fixed length and location, 
while it relies on natural landmarks on the SC itself. Thus it allows for a reliable measurement of localized SC 
volume and its comparison in the same subject over time 46 (Figure 4). 
 
 
 
 
 
 
 
 
 
 
Figure 3. A-C shows a SC segmentation performed with an active surface method, while D-F demonstrates a 
fully automatic SC segmentation.39 
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Figure 4. SC segmentation with Cordial, the cord image analyzer. a) In a first step, a subset of SC voxels 
(green) and background voxels (e.g., cerebrospinal fluid, vertebral bodies; red) are selected manually. In 
addition, an anatomical landmark—the medullopontine sulcus—is defined manually (red dot). b) 
Presegmentation result of the SC (yellow). c) SC surface reconstruction. d) Definition of the cutting planes 
for SC volume calculation  46. 
 
Most of the above mentioned cord volume quantification approaches focused on cervical and mid thoracic 
levels of the SC 27–34,36–39,42–46. In comparison to the cervical and thoracic SC, the lumbar SC poses additional 
challenges because of its location in an environment with a different bone, soft tissue and air composition 
resulting in image distortion and lower signal intensity due to magnetic field inhomogeneities. In addition, the 
lumbar SC is surrounded by multiple spinal roots exiting the spinal canal, which can lead to reduced SC/CSF 
contrast due to partial volume effects and misclassifications of the SC contour.  
Moreover, accurate SC GM segmentation also remains a challenge. While all the above-mentioned 
segmentation algorithms focus on the whole cord, only recently, Yiannakas et al. (2012) demonstrated the 
feasibility to distinguish between the WM and GM by performing manual segmentation 17. As a result of the 
improvement in image quality and post-processing techniques, the first fully automatic SC GM segmentation 
methods were also established in the past few years 47–50. A gold standard pipeline for accurate and 
reproducible SC GM measurements is, however, still a matter of ongoing discussion. 
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1.3. Multiple Sclerosis and Spinal Cord Involvement 
 
1.3.1. Epidemiology and risk factors 
MS is a chronic inflammatory and neurodegenerative disease of the optic nerves, SC, and brain, affecting 
more than 2-3 million people worldwide 51–54. It predominantly affects young adults, and has a huge impact 
functionally, on quality of life, and financially whereas healthcare costs are considerable and rise with 
increasing disability 51–55. Age of onset is usually between 20 and 50 years and women are more often affected 
than men, while the female to male sex ratio seems to be increasing in the last 50 years and is currently 
estimated to be around 3.2:1 56. Despite the fact that a specific etiologic trigger has not been identified, various 
genetic and environmental risk factors, e.g. female sex, carriers of a HLA DRB1*1501 haplotype, viral 
infections, low vitamin D levels, smoking, and others, have been shown to increase the risk of acquiring the 
disease57. Once multiple sclerosis diagnosis is confirmed, older age, male sex, and higher disability at baseline 
are associated with a worse prognosis 58.  
 
1.3.2. Pathogenesis 
MS is generally accepted to be an autoimmune demyelinating disease, although the reason why immune 
responses against CNS antigens are initiated and maintained is currently unclear. Furthermore, there is also 
an ongoing debate about whether the root cause of MS is intrinsic or extrinsic to the CNS. However, both the 
adaptive and the innate immune system have been described in numerous studies to participate in tissue 
damage in MS (Figure 5). Helper (CD4+) and cytotoxic (CD8+) T cells 59, B-lineage cells and respective 
antibody production are involved 60. However, no specific autoantigens interacting with T and B cells have 
been so far confirmed 61,62.  On the other side, blood-borne macrophages 63, microglial cells are (although 
unclear if their role is pathogenic, protective or both) 54,64,65, astrocytes 66 and blood–brain barrier leakage are 
part of the pathogenic processes in MS 67.  
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1.3.3. Pathology 
The hallmarks of MS pathology are inflammation, immune cell infiltration, axonal or neuronal loss, 
demyelination, and astrocytic gliosis 52,54. MS patients demonstrate characteristic lesions, which are 
disseminated in multiple regions of the CNS, including brain WM and GM, brain stem, SC, and optic nerve. 
Besides the latter, temporal distribution represents the second cornerstone of the diagnosis of the disease 68 
(Figure 6).  
Evidence from MRI and pathological assessment (biopsies and autopsies) indicates that early “active” WM 
lesions demonstrate different histopathological patterns of demyelination (described as type I-III) and evolve 
over the course of months 60. However, studies suggest that a single immune-mediated mechanism and thus a 
specific “lesion type” dominates in each MS patient 69. Acute MS plaques show activation of astrocytes and 
microglia and sometimes caspase-independent oligodendrocyte apoptosis 60. After the initial phase, the 
inflammation of a given lesion may resolve or persist leading to a so-called “smoldering lesion”.  
Figure 5. Pathogenetic mechanisms of WM and GM MS lesions 79. 
 Spinal Cord Volume Quantification And Clinical Application In Multiple Sclerosis – C. Tsagkas 
 
15 
 
Demyelinating lesions do not only occur in the WM but can be also located at the WM/GM junction (also 
known as juxtacortical lesions) or even arise entirely in the GM. Brain cortical lesions are shown to be less 
inflammatory than their WM counterparts and have substantially less permeability of the blood–brain barrier 
70. Approximately half of all brain cortical lesions are perivascular, whereas the rest appear adjacent to the 
pial surface of the brain 71–73. In the early stages these lesions are active and correspond to leptomeningeal 
inflammatory aggregates which most likely become inactive during the course of the disease 73. 
Leptomeningeal inflammation has been shown to also organise into self-sustaining lymphoid-like follicles in 
secondary progressive MS 74.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, axonal transections especially in acute MS lesions as well as slow neuronal and axonal degeneration 
in chronically demyelinated lesions lead to irreversible neuronal injury and permanent clinical disability 75,76. 
Chronic neurodegeneration is thought to be a result of impaired axonal transport, mitochondrial dysfunction, 
the loss of myelin trophic support -leading to progressive swelling and cytoskeletal disorganization- and 
increased energy demands related to the upregulation of ion channels 76.  
Figure 6. Imaging and pathological examples of MS lesion location in A) the periventricular white matter 
lesion, B) the subpial cortex, C) the leptomeninges, D) thalamus and pons, E) the spinal cord, F) the optic 
nerve, G) the retina 79. 
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1.3.4. Spinal Cord Involvement 
SC abnormalities have been observed in up to 83% of MS patients, with 60% of them occurring in the cervical 
region 77,78. Patients with progressive MS often demonstrate confluent SC lesions, which appear as diffuse 
MRI abnormalities 77,78. SC lesions mostly arise in the SC circumference, affecting predominantly the dorsal 
WM tracts and the lateral corticospinal tracts and may not respect the SC WM/GM borders 5,77,78 (Figure 8 
and 9). SC lesions have a central diagnostic role and the presence of a single SC lesion is predictive of 
conversion to clinically definite MS 79,80. SC involvement in CIS is also associated with an increased risk of 
future disability 80.  
Figure 7. Axial sections of cervical spinal cord (SC) lesions in multiple sclerosis. (A) Hyperintense signal 
abnormalities on axial fast field echo (FFE) sequences demonstrate lesions in the lateral and posterior 
columns. (B) Hypointense signal abnormalities seen on phase sensitive inversion recovery (PSIR) sequence 
imaging indicate lesions in the lateral and posterior columns. (C, D) Lateral column lesions extending from 
the SC white matter into the gray matter are seen on (C) FFE sequence and (D) PSIR sequence 5.  
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MS is, however, characterized by diffuse damage of the SC. In post mortem studies, axonal density in MS 
was found to be lower by around 60% across all levels and affect all fibers regardless of diameter, whereas 
loss of corticospinal tract fibers may be disproportional to the rest of the SC 81. Demyelination seems to affect 
24–48% of the GM and 11–13% of the WM, with no significant differences across levels. Finally, a significant 
association was detected between focal demyelination and decreased axonal density. 
Figure 8. Transverse, paraffin-embedded sections (thickness: 10 μm) sampled from the same level (the sixth 
cervical nerve) of the spinal cord from a patient with secondary progressive multiple sclerosis. a | SMI-31 (a 
phosphorylated neurofilament) immunostaining shows the anatomical organization of the grey matter (the 
darker core with a butterfly-like shape) and white matter in the spinal cord. b | Myelin basic protein 
immunostaining shows a large lesion of both grey and white matter. Scale bar = 1 mm 5. 
 
Despite the abundancy of focal demyelinating lesions in MS patients, this disorder is generally characterized 
by a weak correlation between lesion load and clinical disability also known as clinical-radiological paradox 
40,82. This paradox is also seen for SC lesional burden. One explanation for that are the repair and compensatory 
mechanisms known to arise following MS-associated CNS injury such as the redistribution and increase of 
the axonal sodium channels 83,84, remyelination 85, recovery of function due to secondary to cortical plasticity 
86 and long-term potentiation of synaptic transmission 87. Another explanation is that -instead of focal 
inflammatory lesions- a diffuse neurodegenerative mechanism is responsible -for the greater part- for the 
patient’s neurologic deficits.  
Given the abovementioned limitations using SC lesion metrics as biomarker in MS, alternative methods that 
have the ability to quantify MS-related SC injury were sought and the main interest was focused on SC 
atrophy. SC atrophy is thought to be the aftermath of neuronal loss and shrinkage, axonal loss and 
demyelination 81,88,89, which seems at best weakly related to focal brain and SC MS lesions 88,90. Therefore, in 
vivo measures of SC atrophy assessed on MRI, e.g. SC volume and SC cross-sectional area, reflect a diffuse 
process. Fortunately, those metrics consistently demonstrate strong correlations with clinical disability 44,45,91–
93.  
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SC atrophy mainly SC volume loss have been shown to occur across all stages of MS (although there are 
conflicting data regarding SC atrophy in clinical isolated syndrome 44,45,91–93) and has been shown to be more 
extensive in progressive forms of the disease in cross-sectional studies 44,94,95. Former studies demonstrate 
controversial results concerning differences in short-term longitudinal SC atrophy assessments between MS 
subgroups. While RRMS display clusters of atrophy primarily localized to the posterior SC, whereas 
progressive MS patients seemed to have more generalized volume loss confined in the posterior and lateral 
columns 96.  
SC GM cross-sectional area changes were also investigated in two recent cross-sectional studies. Schlaeger 
and colleagues observed evidence of GM atrophy of the cervical and thoracic SC compared to healthy controls 
(Figure 10) 95,97. These studies also demonstrated marked GM atrophy in progressive MS subtypes compared 
to RRMS 95,97. More importantly, SC GM atrophy was found to be the most significant correlate of clinical 
disability over brain metrics such as GM and WM 95,97. 
 
 
 
 
 
 
 
 
 
 
Figure 9. A–F) Axial 2‐dimensional phase‐sensitive inversion images at the C2/C3 disk level of multiple 
sclerosis patients95. 
 
Despite the interest raised by cross-sectional and short-term follow-up volumetric SC studies, there is still 
lack in larger scale longer-term longitudinal studies on SC volume loss in MS. This is partly due to the 
technical difficulties discussed before as well as time and financial restrictions for an additional MRI of the 
SC. As a result, there is a knowledge gap on the dynamic changes of SC measures and their association with 
the patient’s clinical picture over time. 
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2. Gaps in research and aims of this PhD thesis 
The overall aims of this thesis were to: i) develop and clinically validate methods for volume quantification 
of the SC and its compartments (GM/WM) suitable for longitudinal assessment and ii) evaluate spinal cord 
volume as a potential valuable biomarker and provide new insights into the contribution of SC pathology to 
the evolution multiple sclerosis. 
 
Manuscript 1:  
As a first step, we aimed to expand the main field of application of our new in-house developed quantification 
software Cordial (Cord image analyzer) for quantification of the lumbar cord. The lumbar cord is of great 
importance for the sensorimotor function of the legs, sexual function, and bladder and bowel control. 
Moreover, volumetric measurements of the lumbar cord may depend on the integrity of all of those structures 
and serve as a potential biomarker e.g. for inflammatory or neurodegenerative disorders (e.g. HTLV-1-
associated myelopathy, MS, neuromyelitis optica, amyotrophic lateral sclerosis, etc.). Such a segmentation 
method for lumbar SC volume would be a major step forward in a number of diseases with affection of the 
lumbar SC in terms of disease monitoring, and development and evaluation of new treatment options. 
In comparison to the cervical and thoracic SC, the lumbar SC poses additional challenges (e.g. environment 
of different bone, soft tissue and air composition leading to magnetic field inhomogeneities; multiple spinal 
roots in close vicinity prone to partial volume effects) and therefore has not been in the focus of method 
development/validation yet. Most recently, the quantification software Cordial was presented with 
longitudinal studies in mind, which provides measurements of SC sections with fixed length and location, 
while it relies on natural landmarks on the SC itself. Thus, it allows for a reliable measurement of localized 
SC volume and its comparison in the same subject over time. Although this method was validated for the 
cervical SC, its features allow a potential application in other SC segments.  
Hence, “Manuscript 1” of this thesis had the aim to verify the accuracy and reproducibility of Cordial for 
quantification of lumbar SC volume. Our objective was to evaluate the performance of this SC volume 
quantification algorithm in MR-images of healthy controls scanned repeatedly and then post-processed by 
multiple “raters”. 
 
Manuscript 2:  
In the past, quantification of the spinal cord predominantly focused on the structural changes as a whole. 
However, histopathological studies show changes of SC GM independently of the surrounding WM and vice 
versa in a large spectrum of neurological conditions. The open question is to what extent each individual 
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compartment is affected and how their respective longitudinal course looks like in vivo. To answer this, not 
only advanced MR imaging methods, but also an automatic segmentation method providing accurate and 
reproducible measurements of each individual SC compartment is needed. 
Fortunately, a novel MRI technique, the Averaged Magnetization Inversion Recovery Acquisitions (AMIRA) 
sequence was developed 21. This technique overcomes the major requirements for reliable quantification of 
SC tissue changes over time. It shows remarkable tissue contrast between GM and WM and has a high in-
plane resolution, which is necessary for a structure with such a small diameter. Despite the latter it is fast with 
low sensitivity to motion.  
Next to the limitations for of high-quality imaging methods of the SC, accurate SC GM/WM segmentation 
also remains a challenge. The above-mentioned in-plane resolution of around 0.5 mm is barely enough to 
visualize the SC’s butterfly-shaped GM structure. Taking into account, that mean SC volume changes in 
disorders such as multiple sclerosis range between 0.5-2.2% per year, it becomes apparent that new accurate 
and reproducible methods for the development of such a biomarker are a difficult task. Hence, a gold standard 
pipeline for accurate and reproducible SC GM measurements is still a matter of ongoing discussion. 
“Manuscript 2” as part of this thesis had the objective to provide a reliable pipeline for the quantification of 
SC GM and WM. To do so, this work analyzed the accuracy and reproducibility of the quantification of SC 
GM and WM with a fully automatic post-processing approach in SC images acquired with a recently proposed 
imaging protocol (including the AMIRA sequence). Our objective was to test the performance of this SC GM 
quantification algorithm in “scan-rescan” MR-images of healthy controls. The SC images were segmented 
manually multiple times by multiple “raters” and then compared with the automatic method. 
 
Manuscript 3 & 4:  
In MS, SC atrophy is common and is thought to be a hallmark of neurodegeneration. It represents a number 
of pathologic processes of the SC such as neuronal loss and shrinkage, axonal loss and demyelination. Despite 
the fact that reproducible measurements of the spinal cord cross-sectional area have been possible for more 
than 20 years and the interest raised so far by cross-sectional and short-term follow-up volumetric SC studies, 
there is a lack of larger scale longer-term longitudinal studies on SC volume loss in this disorder. This is partly 
due to the technical difficulties discussed before as well as time and financial restrictions for an additional 
MRI of the SC in a routine setting. As a result, there is a knowledge gap on the dynamic changes of SC 
measures, their association with the patient’s clinical symptoms over time and the predictive value of this 
potential biomarker. Studies so far have shown controversial result to whether MS disease subtypes differ in 
terms of SC atrophy. 
Hence, “Manuscript 3 & 4” investigated the cervical SCV for atrophic changes over 6 years in an existing 
large cohort of overall 243 MS patients. In particular, the first study (Manuscript 3) analyzed relapse-onset 
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MS patients only, while the second study (Manuscript 4) focused mainly on the PPMS group. One objective 
of those studies was to demonstrate SCV loss occurring over time in these patients and if evident, focus on 
between-group differences. Moreover, the relationship between SCV loss and clinical outcomes as well as the 
relative contribution of SCV loss together with brain atrophy and lesion measurements to the deterioration of 
physical disability were examined. In a last step, these studies verified the hypothesis that SC atrophy may be 
able to predict clinical outcomes later on.
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Abstract 
Objective: To validate the precision and accuracy of the semi-automated cord image analyzer (Cordial) for 
lumbar spinal cord (SC) volumetry in 3D T1w MRI data of healthy controls (HC). 
Materials and Methods: 40 3D T1w images of 10 HC (w/m: 6/4; age range: 18-41y) were acquired at one 
3T-scanner in two MRI sessions (time interval 14.9±6.1d). Each subject was scanned twice per session, 
allowing determination of test-retest reliability both in back-to-back (intra-session) and scan-rescan images 
(inter-session). Cordial was applied for lumbar cord segmentation twice per image by two raters allowing for 
assessment of intra- and inter-rater reliability and compared to a manual gold standard. 
Results: While manually segmented volumes were larger (mean: 2028±245mm3 vs Cordial: 1636±300 mm3, 
p<0.001), accuracy assessments between manually and semi-automatically segmented images showed a mean 
Dice-coefficient of 0.88±0.05. Calculation of within-subject coefficients of variation (COV) demonstrated 
high intra-session (1.22-1.86%), inter-session (1.26-1.84%), as well as intra-rater (1.73-1.83%) 
reproducibility. No significant difference was shown between intra- and inter-session reproducibility as well 
as between intra-rater reliabilities. Although inter-rater reproducibility (COV: 2.87%) was slightly lower 
compared to all other reproducibility measures, between rater consistency was very strong (intraclass 
correlation coefficient: 0.974).  
Conclusion: While under-estimating the lumbar SCV, Cordial yet provides excellent inter- and intra-session 
reproducibility showing high potential for application in longitudinal trials. 
 
Keywords: spinal cord; volumetry; semi-automated segmentation; magnetic resonance imaging; imaging 
biomarker 
 
Key points:  
- Lumbar spinal cord segmentation using the semi-automated cord image analyzer (Cordial) is feasible.  
- Lumbar spinal cord was defined as a 40mm spinal cord segment located 60 mm above the conus medullaris. 
- Cordial provides excellent inter- and intra-session reproducibility in the region of the lumbar spinal cord. 
- Cordial shows high potential for application in longitudinal trials. 
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Abbreviations and acronyms: central nervous system (CNS); coefficient of variation (COV); cerebrospinal 
fluid (CSF); field-of-view (FOV); healthy controls (HC); intra-class correlation coefficient (ICC); 
magnetization-prepared rapid gradient-echo (MPRAGE); spinal cord (SC); spinal cord volume (SCV); 
standard deviation (SD); echo time (TE); repetition time (TR); volumetric interpolated breath-hold 
examination (VIBE) 
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Introduction 
The spinal cord (SC) is affected by a number of inflammatory, hereditary and degenerative diseases of the 
central nervous system (CNS). Pathological changes in this region may cause significant disabling deficits 
including sensorimotor as well as bowel and bladder dysfunction. MR imaging of the SC plays a crucial role 
in the diagnostic process, depicting in vivo pathological processes within and surrounding the SC. Atrophy of 
the cord reflects loss or damage of myelin, axons and neurons and has already been proven to be a valuable 
biomarker correlating well with physical disability 5. 
Despite fast technical developments within the past decades, the anatomical properties of the SC (a relatively 
thin, long and mobile structure) still hamper acquisition of high-quality MR images and reliable quantification 
of SC metrics 5,98–100. Manual segmentation of the cord is not only time-consuming, but also rater-dependent, 
and therefore both, reproducibility and accuracy are compromised. Several semi- and fully-automated 
segmentation techniques have been deployed to overcome these limitations 26,29–38,46,101–103. However, most of 
these approaches focused on cervical and mid thoracic levels of the SC 26,29–31,33,34,36,37,46,101–104. Measurements 
of the lumbar cord volume are still limited due to its anatomical structure and surroundings in the human body 
rendering it susceptible to image artifacts as well as relatively low tissue contrast 3. In comparison to the 
cervical and thoracic SC, the lumbar SC poses additional challenges. It is located in an environment with a 
different bone, soft tissue and air composition resulting in image distortion and lower signal intensity due to 
magnetic field inhomogeneities. In addition, the lumbar SC is surrounded by multiple spinal roots exiting the 
spinal canal, which can lead to reduced SC-cerebrospinal fluid (CSF) contrast due to partial volume effects 
and misclassifications of the SC contour.  
Nevertheless, the lumbar cord is of great importance for the sensorimotor function of the legs, sexual function, 
and bladder and bowel control. It contains not only both afferent and efferent fibers to the lower extremities, 
bladder and bowel, but also nuclei for those pathways (anterior and posterior horns, sacral sympathetic nuclei, 
Onuf’s nuclei, etc.). Volumetric measurements of the lumbar cord may depend on the integrity of all of those 
structures and serve as a potential biomarker for disorders such as spinal cord injury, spinal muscular atrophy, 
HTLV-1-associated myelopathy, tumors, multiple sclerosis, neuromyelitis optica, amyotrophic lateral 
sclerosis, etc.) 2,3.  
In this study, we validated the precision of the semi-automated cord segmentation tool Cordial (cord image 
analyzer) in terms of its reliability and reproducibility in segmenting the lumbar SC of healthy controls (HC) 
in one 3T-scanner 26,46,101. This approach is able to provide SC volume (SCV) measurements of fixed length 
and location in relation to the conus medullaris. We hypothesize that Cordial could deliver reliable lumbar 
cord volume quantifications, providing efficient and reliable analyses for studies with longitudinal design. 
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Materials and methods 
Subjects & MRI acquisition 
10 HC (6 women; mean age +/- standard deviation (SD): 28.7±7.3; age range 18-41 years) were scanned on 
one 3 Tesla whole-body MR scanner (Prisma, Siemens Medical, Erlangen, Germany) with a T1w fat-
suppressed volumetric interpolated breath-hold examination (VIBE) sequence. The sequence parameters 
were: repetition time (TR) of 7 ms, echo time (TE) of 2.46 ms, Matrix 256 x 256 and field-of-view (FOV) of 
256 x 256 mm2, 160 transverse slices with an isotropic resolution of 1x1x1 mm3, covering 9.8 cm of the 
lumbar spine, located between the 11th thoracic vertebral body and 3rd lumbar vertebral body, acquisition time 
5:16 min. Sagittal images were reconstructed from the axial VIBE images. To ascertain reproducibility the 
sequence was centered on the superior endplate of the most caudal vertebral segment containing the SC. 
Each subject underwent two MRI sessions. In each MRI session subjects were scanned twice (back-to-back) 
with repositioning between scans. The second session took place with a mean time interval of 14.9±6.1 days, 
allowing for scan-rescan tests. All subjects gave written consent. The experimental procedures conformed to 
the Declaration of Helsinki and the study protocol was approved by the local ethics committee. 
 
Lumbar SC segmentation 
Segmentations were performed in a manual (as a gold standard) and semi-automated fashion.  
The manual segmentations of the spinal cord were performed on the first scan of the first MR-imaging session 
of each HC by two expert raters (C.T; A.A.) using ITK-Snap (Version 3.6.0). The latter were visually 
inspected and, if necessary, adjusted by two experienced radiologists (J.W.; A.F.). A consensus reading 
between all four raters (C.T.; A.A.; J.W.; A.F.) resulted in a final single manual spinal cord segmentation per 
scan, which was then deployed as the gold standard and used for the comparison with the automated 
segmentations (described below). 
In a second step all scans were segmented using the semi-automated tool Cordial, described in detail by 
Amann et al. 46,101,102. Briefly, the method comprises three separate steps: pre-segmentation, segmentation 
refinement, and volumetric measurement. While the pre-segmentation requires user interaction of about 2–5 
min. per scan, the subsequent steps are fully automated. During pre-segmentation an anatomical marker was 
set at the tip of the conus medullaris, defined as the most distal point on the lowest axial image in which spinal 
cord tissue was identifiable with confirmation on sagittal images (on average between level L1 and L2). The 
segmentation of the caudal part of the lumbar cord including the conus medullaris (region below lower blue 
border on Figure 18) was limited by artifacts (low contrast between the SC and the surrounding structures 
such as spinal nerves, spinal nerve roots, vertebrae etc.). These parts were therefore excluded from the 
calculation of the volume. The segmentation of the upper part was restricted from the FOV-limits. In the light 
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of the aforesaid, the measured volume (hereinafter referred to as SCV) was located 60 mm above the 
previously fixed marker at the conus medullaris and comprised a segment of 40mm along the SC center line 
(for details see Figure 10). After completion of the pre-segmentation and the segmentation refinement the 
MR-images were visually inspected for quality. All images were segmented twice by two experienced raters 
(C.T; A.A.), with an interval of at least 7 days between the two evaluations (runs). 
 
Figure 10. Final lumbar spinal cord 
(SC) segmentation (red lines) with 
Cordial of a representative subject.  
Blue lines mark the region of 
maximum feasible SC volume over 
all subjects (starting 60mm above the 
manual marked tip of the conus 
medullaris (red dot) over a defined 
cord centre line distance of 40mm). 
Low image and segmentation quality 
restrict measurement beyond the 
blue lines in the majority of scans. 
 
Statistical Analysis 
All analyses were performed using R Version 3.2.3 (http://r-project.org/). 
The reproducibility of SCV in terms of intra-session and inter-session, as well as intra- and inter-rater 
reliability of Cordial was assessed using the coefficient of variation (COV) independently for each subject. 1) 
Paired back-to-back acquisitions allowed for computation of intra-session variability (reflecting noise and 
segmentation errors), whereas 2) paired scan-rescan acquisitions were used for computation of inter-session 
variability (depicting biological changes (e.g. hydration status) and/or differences due to repositioning of the 
subject). 3) Paired measurements of the two runs by the same rater were used for intra-rater reproducibility, 
which corresponds to variability depending on the segmentation method and image quality. 4) Paired 
measurements of single images segmented by different raters were deployed for inter-rater reliability. The 
latter corresponds to variability depending on the application of the method by different raters (emerging 
during the pre-segmentation step of the method).   
For assessment of the respective COV the standard deviation of these paired differences for each subject was 
defined as: 
 Spinal Cord Volume Quantification And Clinical Application In Multiple Sclerosis – C. Tsagkas 
 
28 
 
SDn = √∑(𝛥𝑆𝐶𝑉𝑛
𝑖 − 𝛥𝑆𝐶?̃?𝑛)
2
/ (𝑚𝑛 − 1) , 
where 𝛥𝑆𝐶𝑉𝑛
𝑖 and 𝛥𝑆𝐶?̃?𝑛, the SCV difference of the ith paired measurements and the mean SCV difference of 
the nth subject, over the m pairs. Subsequently the respective intra- and inter-session as well as intra- and 
inter-rater COVs of each individual patient was computed in the form of a percentage as follows: 
COVn = 
𝑆𝐷𝑛
𝑆𝐶𝑉?̃?
∗  100 , 
where 𝑆𝐶𝑉?̃? the arithmetic mean of the SCV values used for the calculation of the respective nth subject’s 
paired differences. Comparisons between intra- and inter-session variability and between raters were 
performed through 2-paired t-tests, with Bonferroni corrections for multiple comparisons where applicable. 
As a relative measure of reliability which measures the contribution of between-rater variance to total variance 
we calculated the intra-class correlation coefficient (ICC), using a two-way linear mixed effect model with 
random intercepts allowing for random between subject variability and different raters as a fixed effect. ICC 
is capable of measuring the ability of a method to detect differences between subjects consistently, and 
typically ranges between 0–1, with values close to 1 indicating high reliability. 
Further, in order to measure Cordial’s accuracy, Dice-coefficients as well as symmetric Hausdorff distances 
and symmetric mean surface distances between the manually and semi-automatically segmented images were 
calculated. Manually segmented cord volumes were compared to Cordial’s results using 2-paired t-tests. 
Association between SCV, sex and age were investigated using analysis of covariance (ANCOVA) with type 
III calculation of the sum of squares.  
 
Results 
All 40 lumbar cord segmentations of 10 HC were accepted after quality control for image quality and artifacts 
for both raters and runs (Figure 11). 
For all HC, mean ± SD SCV was 1652±262mm3 as calculated through 4 MRI scans, segmented by two raters, 
twice per rater (16 measurements per subject). SCVs and COVs for different raters and runs as well as 
comparisons between different types of reliabilities are displayed in Table 1 and demonstrated in Figure 12. 
All COVs were less than 3%. Mean intra-session, inter-session and intra-rater reproducibility as measured by 
COV were in the range of 1.22-1.86%, 1.22-1.84% and 1.73-1.83% respectively. Intra- and inter-session 
reliability as well as intra-rater reliability between the two raters did not significantly differ as shown by paired 
two sample t-tests. Inter-rater reproducibility (mean: 2.87%) was lower than all other reproducibility 
measures. When using a two-way linear mixed effect model with raters as fixed effect, ICC was 0.974. This 
indicates a very strong consistency of lumbar SC measurements between the two raters. 
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Using ANCOVA with the SCV as dependent variable, men (F(1,7)=6.14, r=0.68) had significantly larger 
volumes compared to women (men: 1986±77mm3, women: 1489±53mm3, p<0.05), while age (F(1,7)=0.95, 
r=0.35) had no significant effect. 
Accuracy assessments showed a mean Dice-coefficient between manually and semi-automatically segmented 
images of 0.88 ± 0.05. The mean symmetric Hausdorff distance was 1.55±0.34 mm and the mean symmetric 
mean surface distance was 0.47±0.19 mm. The manually segmented volumes (mean: 2028±245mm3) were 
significantly larger (p<0.001) in comparison to the results of Cordial (mean: 1636±300 mm3). 
 
Figure 11. Successful spinal cord segmentations of the four scans of one representative healthy control. Scan 
1 and 2 were performed in the 1st session, whereas scan 3 and 4 in the 2nd session. 
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Table 1. Spinal cord volumes and coefficients of variation of both raters and runs. 
 
 
Abbreviations: SCV= spinal cord volume; COV= coefficient of variation; ns= not significant 
All values are shown as follows: mean ± standard deviation. P-values were obtained through paired 2 sample t-tests. Comparisons between the intra-session and 
inter-session reliability were conducted between COVs of a single run by a single rater. In comparisons between the inter-rater and intra-rater reliability of 
Cordial, Bonferroni correction was applied.
Rater Run 
SCV 
(mm3) 
Intra-
session COV 
(%) 
Inter-session 
COV (%) 
Intra-rater 
COV (%) 
Inter-rater 
COV (%) 
p-value 
Intra-session vs. 
Inter-session 
Intra-rater 
Between Raters 
Rater 1 
Run 1 1620±270 1.22±0.95 1.26±0.60 
1.73±1.43 
2.87±1.20 
ns 
ns 
Run 2 1653±261 1.50±1.33 1.42±0.97 ns 
Rater 2 
Run 1 1673±261 1.63±0.97 1.53±0.90 
1.83±0.91 
ns 
Run 2 1661±264 1.86±1.12 1.84±0.91 ns 
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Figure 12. Bland-Altman plots. Intra-session A), Inter-session B), Intra-rater C) and Inter-rater D) paired 
differences (y-axis) plotted against mean SCV (x-axis) of the respective scans. Dashed lines indicate mean 
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difference and limits of agreement (mean difference ±1.96 standard deviation of the paired difference). SCV 
= spinal cord volume (x-axis), ΔSCV = spinal cord volume differences (y-axis). 
 
Discussion 
While various SC segmentation techniques have been applied in the cervical and thoracic cord  26,29–
31,33,34,36,37,46,101–104, little is known regarding volumetry of the lumbar cord 105. In this study, we successfully 
deployed the semi-automatic SC segmentation tool Cordial 46 to measure the lumbar SCV in healthy controls 
producing robust results. 
Cordial showed similar intra- and inter-session variability with a mean COV range of 1.22-1.86%, indicating 
high reliability, precision and consistency of the SCV measurements of back-to-back and scan-rescan MRI 
acquisitions. Repositioning did not seem to have significant effect on the variation of the measurements, 
making Cordial an appropriate choice for longitudinal studies. Intra-rater reproducibility showed comparable 
quality with a mean COV range of 1.73-1.83%, which was similar for both raters. 
Of all results inter-rater reliability was lowest (mean COV of 2.87%), although the measurements of the 2 
raters were highly consistent. Correct manual positioning of our anatomical marker at the tip of the conus 
medullaris was challenging even for experienced radiologists. Due to suboptimal contrast between the cord, 
surrounding CSF and spinal nerves, the exact positioning of the tip of the conus medullaris was at times 
difficult to discern. A difference of just one or two slices results in increased between-measurement variances. 
This remains a problematic issue for a fully manual or semi-automated approaches such as Cordial and always 
has to be taken into account. It could be overcome by using the same reader for all images of a study, however 
this would be impractical in a clinical setting. In addition, in terms of SC-CSF contrast the use of others 
sequences, e.g. 3D magnetization-prepared rapid gradient-echo (MPRAGE) or combination of T1- and T2- 
weighted contrasts might be better suited than T1w fat suppressed VIBE alone.  
We saw the known effect of male sex on CNS structures also in the spinal cord 103,106,107, showing larger 
volumes in men than women. The missing aging effect is not surprising and explained by the young age range 
of our subjects as previously shown in cervical and thoracic SC volumes 103 as well as the small sample size. 
However, conclusions about the association of age and sex are limited by our small sample size. 
Cordial demonstrated high accuracy in comparison to a consensus reading manual segmentation, deployed as 
a gold standard. Nevertheless, the segmented spinal cord volume measured with Cordial underestimated the 
spinal cord volume compared to the manually segmented spinal cord. The conservative spinal cord 
segmentation approach of Cordial is also evident in the axial slices of Figure 13. This should be taken into 
consideration in future analyses when comparing Cordial with other segmentation methods. Likewise, 
longitudinal studies using Cordial should focus only on the relative changes of the SCV. 
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In comparison to the application of Cordial in 3D magnetization-prepared rapid gradient-echo and T2-
weighted 3D turbo spin echo images of the upper cervical SC in a previous study 102, our study demonstrated 
a marginally lower reliability, reproducibility as well as accuracy which most probably reflects the lower 
image quality of the lumbar SC MR-imaging. The different environment and surrounding structures of the 
lumbar SC result in magnetic field inhomogeneities and lower SC-CSF contrast. Moreover, we attempted to 
validate Cordial in 3D T2-weighted SPACE images to compare the software’s reliability in a T2-weighted 
contrast. Unfortunately, Cordial failed to deliver high quality segmentations of the lumbar SC in this data set 
(Figure 13). We believe that the spinal nerve roots in these heavily T2-weighted images generate a stronger 
signal compared to T1-weighted images, making them isointense to the spinal cord and therefore posing 
difficulties for an accurate segmentation. Integration of multiple contrasts in the segmentation algorithm in 
the future may improve precision of Cordial within this region. As an important limitation of our study, it 
should be mentioned, that Cordial was not able to deliver a reliable volumetry of the conus medullaris, which 
is a relevant spinal cord segment for a number of spinal cord disorders. In our view, this is, at least partly, due 
to the low SC-CSF contrast rendering it difficult to separate conus tissue from surrounding spinal nerve roots.  
Figure 13. Lumbar spinal cord (SC) segmentation (red lines) using Cordial in a representative subject. A) 
Successful segmentation on 3D T1-weighted fat-suppressed VIBE images. As demonstrated in the sagittal 
image, Cordial aborts the segmentation in the region of the conus medullaris. Of note, Cordial shows a rather 
conservative segmentation with its outer boundary slightly within the cord’s surface. B) Cordial failed to 
deliver high quality segmentations of the whole lumbar SC in 3D T2-weighted SPACE images of the same 
subject due to artifacts based on the spinal nerve roots exits and nerve roots adjacent to the spinal cord within 
this region. 
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Lastly, Cordial is to this point limited to whole-cord measurements and is currently not able to perform any 
other measurements such as grey and white matter measurements. 
In conclusion, Cordial results in the lumbar cord were highly reliable and reproducible. Cordial is therefore 
suitable for the use in longitudinal trials. The COV values calculated in this study can be used for effect size 
calculations for SCV for studies using the same processing pipeline. 
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3.2. Automatic Spinal Cord Gray Matter Quantification: A Novel Approach 
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Abstract 
Background and purpose: To assess the reproducibility and accuracy of cervical spinal cord (SC) gray 
matter (GM) and white matter (WM) cross-sectional area measurements using averaged magnetization 
inversion recovery acquisition (AMIRA) images and a fully-automatic post-processing segmentation 
algorithm.  
Materials and Methods: The cervical SC of 24 healthy subjects (14 female, age 40±11 years) was scanned 
in a test-retest fashion on a 3T MRI-system. Twelve axial AMIRA slices were acquired over a 48mm cord 
segment. GM and WM were both manually segmented by two experienced readers and compared to an 
automatic variational segmentation algorithm with a shape prior modified for 3D data with a slice similarity 
prior. Precision and accuracy of the automatic method were evaluated using coefficients of variation (CV) 
and Dice similarity coefficients (DSC). 
Results: Mean GM area was 17.20±2.28mm2 and mean WM area 72.71±7.55mm2 using the automatic 
method. Reproducibility was high for both methods, while being better for the automatic approach (all mean 
automatic CVs ≤4.77%, all differences p<0.001). The accuracy of the automatic method, as compared to the 
manual reference standard, was excellent (mean DSC:  0.86±0.04 for GM and 0.90±0.03 for WM). The 
automatic approach demonstrated similar CVs between intra- and inter-session reproducibility as well as 
among all acquired SC slices. 
Conclusion: Our novel approach including the AMIRA-sequence and a fully-automated post-processing 
segmentation algorithm demonstrated an accurate and reproducible SC GM and WM segmentation. This 
pipeline is promising for both the exploration of longitudinal structural GM changes and application in 
clinical settings in disorders affecting the SC.
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Abbreviations 
SC=spinal cord; magnetic resonance imaging=MRI; gray matter=GM; white matter=WM; cerebral spinal 
fluid=CSF; averaged magnetization inversion recovery acquisitions=AMIRA; 3 dimensional=3D; total 
spinal cord=TSC; coefficients of variation=CV, dice similarity coefficients=DSC; hausdorff distances=HD; 
multivariate one-way analysis of variance=MANOVA.
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Introduction 
The human spinal cord (SC) can be affected by numerous neurologic disorders of variable pathophysiology 
(e.g. genetic, inflammatory and demyelinating, degenerative etc.) 108,109 and magnetic resonance imaging 
(MRI) is a valuable part of the  diagnostic work-up in patients with suspected intramedullar pathology 2,5. SC 
gray matter (GM) and white matter (WM) can be involved to various extent not only between different SC 
disorders but also between patients suffering from the same disease (e.g. multiple sclerosis, amyotrophic 
lateral sclerosis) 95,110. Hence, quantification of SC compartments may add to our understanding of SC 
pathology 95,110 and hopefully help in the management of individual patients in the future.  
However, the SC presents additional challenges for MRI. The SC is surrounded by a number of different tissue 
types including cerebral spinal fluid (CSF), bone and air. This creates significant signal inhomogeneities along 
this thin, elongated structure 1–3,5. As a result, “conventional” SC MRI was – until recently – not able to 
differentiate sufficiently between SC GM, WM and CSF. In the last years, first attempts towards this 
differentiation using a series of acquisition approaches were made 17–20. More recently an averaged 
magnetization inversion recovery acquisitions (AMIRA) sequence was proposed, delivering a notable SC 
GM/WM contrast while maintaining short acquisition times at the same time 21. The latter is especially 
important for imaging small-sized structures (like the SC GM/WM) in patients with disabilities having a short 
time window where they can lie still. 
Moreover, accurate SC GM segmentation remains challenging. First, manual approaches demonstrated the 
feasibility to distinguish between WM and GM 17. However, manual approaches require a considerable 
amount of time, are prone to error and demonstrate significant inter-observer and intra-observer variability. 
As a result of improvements in image quality and post-processing techniques, the first fully automatic SC GM 
segmentation methods were established in the past few years 47–50. These methods have deployed atlas-based 
GM segmentation algorithms, which may however lead to misestimations or segmentation errors especially 
in case of pathology, image artifacts or large between-individual anatomical variations 111,112. A non-invasive 
broadly accepted reference standard for accurate and reproducible SC GM measurements is still a matter of 
ongoing discussion. 
In this study, we validate a fully automatic method for SC GM and WM segmentation in terms of its 
reproducibility and accuracy in segmenting the cervical SC of healthy controls against a manual segmentation. 
The proposed approach utilized a variational segmentation algorithm with a shape prior 113 modified for 3 
dimensional (3D) data with a slice similarity prior on AMIRA images.  
 
Materials and Methods 
Subjects & MRI acquisition 
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24 healthy subjects (14 female, age 40±11 years) were scanned in a test-retest fashion on a 3T whole-body 
MRI system (Magnetom Prisma, Siemens). All subjects gave written consent. Experimental procedures 
conformed to the Declaration of Helsinki and the study protocol was approved by the local ethics committee. 
We acquired 12 axial AMIRA images 21 (FOV = 128x128mm2, slice thickness 8mm, 4mm slice overlap, in-
plane resolution = 0.67x0.67mm2, TEbSSFP = 2.14 ms, TRbSSFP = 5.13 ms, signal averaging = 1, acquisition time 
= 51s per slice) over a 48mm cervical SC segment, approximately extending from the C2-C5 vertebral level21. 
The most rostrally acquired slice was placed with its lower surface adjacent to the most rostral surface of the 
C2/C3 intervertebral disc. For precise positioning of each individual slice and its orthogonal angulation to the 
course of the SC, a strongly T2 weighted TSE with high contrast between CSF and SC was used as a reference. 
For each slice, the AMIRA approach acquired eight images of considerably different tissue contrast between 
GM, WM and CSF with TIeff  = [97.1; 158.7; 220.2; 281.8; 343.3; 404.9; 466.5; 528.0] ms. Averaging the first 
five images enhances the GM/WM CNR, whereas averaging the last three images clearly improves the 
WM/CSF CNR (Figure 1). For more details on the AMIRA sequence, please see Weigel et al. 2018 21. 
Each subject was scanned three times in one MRI session. The first two scans were performed in a back-to-
back fashion without repositioning to allow for intra-session comparisons. The third scan was conducted after 
patient repositioning to allow for inter-session comparisons. 
All scans underwent basic pre-processing including 2D and 3D correction for field inhomogeneities using the 
scanner software prior to segmentation. To minimize numerical errors of the validation metrics, we performed 
a 5-fold in-slice upsampling of the slices using the Lanczos-3 interpolation kernel.  
Each subject was scanned three times in one MRI session. The first two scans were performed in a back-to-
back fashion without repositioning to allow for intra-session comparisons. The third scan was conducted after 
patient repositioning to allow for inter-session comparisons.  
 
SC segmentation 
As proposed in a previous study 113, a variational segmentation approach based on the continuous min -cut 
max-flow framework was used,  which includes total variation regularization to segment WM and GM. The 
min-cut max-flow’s capacity functions are modeled using edge, region, and prior information as well as an 
appearance model built from manual segmentations. Aiming for high accuracy, the proposed approach prefers 
the actual image's intensities and tries to include prior information as little as possible, which regularizes for 
higher precision. Compared to the previous study 113, we added a slice similarity prior 102, included all 
inversion images of one slice (Figure 1) into the calculation of the max-flow’s capacity functions and improved 
the GM and WM principal component appearance models with posterior appearance models 114.  
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Figure 14. Exemplary axial AMIRA slice of one representative volunteer at the C4 level. a-h) Eight images of different tissue contrast acquired by the AMIRA 
sequence, shown in chronological order from lowest to highest inversion time. i) Average image from a→e in full view, which delivers a high contrast-to-noise-
ratio for GM/WM. j) Average image from f→h, which delivers a high contrast-to-noise ratio for SC/CSF. k) Same average image as in i) but histogram-
equalized and zoomed.
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As a first step of the algorithm to align the 12 slices, the images are center cropped and slice-wise successively 
co-registered rostral to caudal using translations in pixel size steps to prevent further interpolation. Then, the 
algorithm automatically locates and delineates the ring-shaped CSF from its surroundings and extracts the 
cross-sectional SC surface. Finally, it uses the previously segmented SC surface as a mask for GM/WM 
differentiation. An illustration of the algorithm is shown in Figure 15. Segmentations were achieved in a leave-
one-subject-out cross-validation, that is: with the currently segmented subject being left out in the used 
appearance model. 
The segmentation algorithm was implemented in MATLAB.  Processing time on an Intel Xeon CPU E5-2620 
v3 @ 2.40GHz is around one minute for each segmentation step (CSF-SC and WM-GM segmentation), and 
less than 8 GB of RAM are used to segment a stack of 12 slices. Code is available on [github link]. 
Two experienced raters (C.T.; A.A.) were involved in the manual segmentations. Both raters had more than 4 
years experience in neuroimaging research including SC volumetric studies.  In a first step, this was conducted 
on the average of the last three AMIRA images for total SC cross-sectional area. Using the already delineated 
total SC masks, manual segmentations of the GM and WM cross-sectional areas were then performed on the 
average of the first five AMIRA images (Supplementary Figure 1). C.T. segmented all images once. These 
results were further applied as “manual reference standard”. C.T. also conducted a second “run” of 60 
randomly selected slices to assess intra-rater comparisons. This second “run” was conducted with slightly 
different contrast adjustments than the first in order to evaluate the robustness of intra-rater manual 
segmentation. A.A. segmented all images of the first scan of all 24 healthy controls to allow for inter-rater 
comparisons.  
In order to evaluate the performance of our method on SC slices, in which the fully automatic approach failed 
(in total 12% of acquired slices, see also “Results”), we applied a semi-automatic approach as follows: the 
SC/CSF boundaries were segmented manually (manual reference standard) and segmentation of the GM and 
WM was then performed using the fully automatic approach described above given the manual total SC masks. 
In order to compare our automatic method with currently available algorithms, we tested the iterative non-
local STAPLE (iNLS) 115  on our AMIRA images using the algorithm in the SCFusion_Demo package*. 
Asman et al. use atlases consisting of SC GM-WM contrast images and SC-GM-WM manual reference 
standard segmentations, which are rigidly registered to the target slice and fused together with the most fitting 
manual reference standard segmentation as an estimation of the targeted segmentation. We built our own 
atlases and tested iNLS in a leave-one-subject-out fashion.
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Figure 15. Flow-chart of the automatic segmentation pipeline. As a first step of the algorithm to align the 12 slices, the images are center-cropped and slice-
wise successively co-registered rostral to caudal using translations in pixel size steps to prevent further interpolation. Then, the algorithm automatically 
locates and delineates the ring-shaped CSF from its surroundings and extracts the cross-sectional SC surface. Finally, it uses the previously segmented SC 
surface as a mask for GM/WM differentiation. The iterative steps of CSF segmentation are shown as a zoomed-in view. GM segmentation uses essentially the 
same steps and is thus not shown in detail. 
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Supplementary figure 1. Manual segmentations of acquired axial AMIRA slices. In a first step, the CSF 
was manually segmented using the average of the last three AMIRA images. The CSF “mask” was then 
overlaid on the average of the first five AMIRA images. Subsequently, the SC GM was also manually 
segmented.
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Statistical Analysis 
Intra- and inter-session as well as intra- and inter-rater reproducibility of the two approaches were evaluated 
using coefficients of variation (CV), Dice similarity coefficients (DSC) and Hausdorff distances (HD). The 
accuracy of the automatic method compared to the manual reference standard was evaluated using DSC and 
HD. CVs between two masks A and B were calculated with the following formula: 
𝐶𝑉 = √2 ×
|𝐴 − 𝐵|
|𝐴 + 𝐵|
% 
DSCs were calculated as follows: 
𝐷𝑆𝐶 = 2 ×
|𝐺𝑇 ∩ 𝐴𝑀|
|𝐺𝑇| +  |𝐴𝑀|
 
HDs were calculated as follows: 
𝑑(𝑋 → 𝑌) = max(𝑑𝑖
𝑋→𝑌, 𝑖 = 1 … 𝑁𝑋) 
𝐻𝐷 = max(𝑑(𝐺𝑇 → 𝐴𝑀), 𝑑(𝐴𝑀 → 𝐺𝑇)) 
where d is the Euclidean distance between voxel x and y. 
Because of non-normally distributed data, we performed a square root transformation of the CV, a cubic 
transformation of the DSC and a logarithmic transformation of the HD before conducting all t-test analyses 
and MANOVA.  2-paired t-tests were performed for the following comparisons after controlling for normal 
data distribution: 1) manual segmentation versus automatic method reproducibility, 2) manual segmentation 
versus automatic method total SC, WM and GM cross-sectional area. For the automatic method, differences 
in measures of reproducibility and accuracy a) between intra-session and inter-session b) between GM, WM 
and total SC and c) between the axial slices’ levels (1→12) were investigated using multivariate one-way 
analysis of variance (MANOVA). Additional Tukey’s post-hoc-tests were conducted, where applicable. 
 
Results 
In total, 864 slices were acquired from 24 volunteers with 12 slices per scan, performed a total of three times 
for each subject. Out of 864 acquired axial SC slices, nine were excluded from further analysis, because of 
severe imaging artifacts. The automatic method successfully segmented 88% (752 slices) of all remaining 
slices. Because of imaging artifacts, localization problems, or posterior gaps of the CSF, 8% of all slice-wise 
SC segmentations and 4% GM segmentations would have needed further manual interventions and thus were 
excluded from the reproducibility analysis. 
Cross-sectional SC measurements 
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 Mean total SC area was 89.98 ± 7.88mm2, mean WM area 72.71 ± 7.55mm2 and mean GM area 17.20 ± 
2.28mm2 as measured by the automatic method. Compared to the manual reference standard, the automatic 
method delivered significantly higher total SC and WM area as well as significantly lower GM area (86.88 ± 
11.87, 69.18 ± 10.16 and 17.77 ± 3.05 respectively, all p<0.001). Cross-sectional areas per slice of automatic 
method are shown in Figure 16. 
 
Figure 16. Cross-sectional areas of total spinal cord (TSC), white matter (WM) and grey matter (GM) per 
axial slice, as measured by automatic segmentations. Notice the slight increase of TSC and the marked GM 
cross-sectional area increase caudally, which corresponds to the cervical SC enlargement. The light grey 
area depicts the limits of ± one standard deviation. 
 
Reproducibility 
Measurements of intra- and inter-session as well as intra- and inter-rater reproducibility are displayed in Table 
2. Reproducibility of SC GM and WM is also depicted per slice in Figure 17. All mean CVs of the automatic 
method were ≤4.77% and mean DSC ≥0.88 between scans and raters. The latter was significantly better than 
for the manual segmentation (all p<0.001). 
Using MANOVA with DSC, HD and CV as multivariate outcome, a significant difference between intra- and 
inter-session reproducibility for total SC, WM and GM using the automatic method was shown (p<0.001 for 
all 3 models). However, CVs differed only for WM and total SC (p<0.05 and p<0.001 respectively), but not 
for GM. In our automatic method, intra- and inter-session reproducibility was significantly decreasing in the 
order total SC→WM→GM (all p<0.001), as shown by MANOVA and post-hoc tests. No difference was 
found in intra- and inter-session reproducibility between slices for GM, but a significant decrease was found 
for WM (both p<0.001) and total SC (p<0.05 and p<0.001 respectively) in caudal slices, as shown by 
MANOVA. However, CVs were similar for all SC metrics between all slices. 
 
Accuracy 
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Measurements of accuracy of our fully automatic method compared to a manual reference standard are shown 
in detail in Table 3 and are also displayed per slice in Figure 18. The automatic method showed a mean DSC 
≥0.86 in all SC metrics. Accuracy was significantly decreasing in the order total SC→WM→GM (all 
p<0.001), as shown by MANOVA and post-hoc tests. In MANOVA, accuracy was lower for GM (p<0.05) 
and total SC (p<0.001) in caudal slices, but not for WM. However, DSC was similar between acquired slices 
for total SC.  
Measurements of accuracy of the initially discarded SC slices (12% of all acquired AMIRA slices) analyzed 
in a semi-automatic fashion are also shown in Table 3. The semi-automatic approach showed a mean DSC of 
≥0.83 in both GM and WM. When compared to the fully automatic approach on the initially non-discarded 
SC slices, a statistically significant accuracy decrease was observed in the semi-automatic approach (both 
p<0.001). 
 
Comparison with the iterative non-local STAPLE algorithm 
In comparison to the original study 23 performed on T2* MR-images, the application of the iterative non-
local STAPLE algorithm in our AMIRA images showed a higher accuracy. Mean DSC and HD for the total 
SC, GM and WM were as follows: total SC: mean DSC 0.93 ± 0.03 (median 0.94), mean HD 0.96 ± 0.39mm 
(median 0.84mm); GM: mean DSC 0.80 ± 0.06 (median 0.82), mean HD 1.09 ± 0.42mm (median 1.04mm); 
WM: mean DSC 0.87 ± 0.04 (median 0.88), mean HD 0.98 ± 0.37 (median 0.89mm).23 Moreover, our 
proposed automatic method had higher accuracy for all total SC, WM and GM compared to the iterative non-
local STAPLE algorithm in our AMIRA images (all p<0.001).
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Table 2. Grey matter, white matter and total spinal cord reproducibility measurements. 
Parameter 
GM WM TSC 
MAS vs AM 
MAS AAMM MAS AMAM MAS AM 
Intra-session 
n=240 
CV (%) 5.54 ± 4.14 4.10 ± 3.48 3.69 ± 3.23 2.54 ± 2.69 2.99 ± 2.73 1.64 ± 1.63 
GM: p<0.001 
WM:  p<0.001 
TSC:  p<0.001 
 
DSC 0.86 ± 0.03 0.89 ± 0.03 0.93 ± 0.02 0.95 ± 0.02 0.97 ± 0.01 0.98 ± 0.01 
GM:  .  
WM:  p<0.001 
TSC:  p<0.001 
HD (mm) 0.64 ± 0.22 0.63 ± 0.39 0.54 ± 0.13 0.54 ± 0.24 0.44 ± 0.17 0.32 ± 0.15 
GM: = 77 
WM: p=0.80 
TSC:  p<0.001 
Inter-session 
n=454 
CV (%) 6.34 ± 4.66 4.77 ± 4.71 4.68 ± 3.75 2.95 ± 2.58 3.75± 3.13 2.21 ± 1.93 
GM:  .  
WM:  p<0.001 
TSC:  p<0.001 
DSC 0.85 ± 0.03 0.88 ± 0.04 0.92 ± 0.02 0.94 ± 0.02 0.97 ± 0.02 0.98 ± 0.01 
GM:  p 0.001 
WM:  p<0.001 
TSC:  p<0.001 
HD (mm) 0.68 ± 0.24 0.71 ± 0.46 0.58 ± 0.16 0.59 ± 0.28 0.50 ± 0.19 0.37 ± 0.14 
GM: = 1  
WM: p=0.45 
TSC:  p<0.001 
Intra-rater 
n=60 
CV (%) 19.18 ± 12.16 0 ± 0 4.14 ± 3.34 0 ± 0 1.17 ± 1.92 0 ± 0 n.a. 
DSC 0.85 ± 0.07 1 ± 0 0.96 ± 0.02 1 ± 0 0.99 ± 0.01 1 ± 0 n.a. 
HD (mm) 0.62 ± 0.30 0 ± 0 0.44 ± 0.15 0 ± 0 0.20 ± 0.13 0 ± 0 n.a. 
Inter-rater 
n=283 
CV (%) 12.03 ± 8.87 n.a. 8.06 ± 6.15 n.a. 6.50 ± 5.17 n.a. 
 
n.a. 
 
DSC 0.85 ± 0.05 n.a. 0.90 ± 0.04 n.a. 0.95 ± 0.03 n.a. n.a. 
HD (mm) 0.75 ± 0.32 n.a. 0.75 ± 0.27 n.a. 0.68 ± 0.34 n.a. n.a. 
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Abbreviations: MAS = manual segmentations; AM = automatic segmentations; GM = grey matter; WM = white matter; TSC = total spinal cord; CV = coefficient 
of variation; DSC = Dice coefficient; ns = not significant; n signifies the number of MRI axial slices taken into account for each parameter; n.a. = not applicable. 
All values are shown in the form: mean ± standard deviation. P-values were obtained through paired 2 sample t-tests (alpha = 0.05), after performing a square 
root transformation of the CV, a cubic transformation of the DSC and a logarithmic transformation of the HD. 
 
 
 
Figure 17. Comparison between the reproducibility of manual and automatic measurements (AM) of spinal cord grey matter (GM) and white matter (WM) per 
axial slice. Intra-session and inter-session reproducibility is assessed in terms of Dice coefficients (DSC; graphic 1+2) and coefficients of variation (CV; 
graphic 3+4). Manual and automatic inter-session reproducibility is shown dark grey, whereas manual and automatic intra-session reproducibility is shown in 
light grey. Error bars display mean values ± 0.2 standard deviations. 
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Figure 18. Accuracy measurements in terms of Dice coefficients (DSC; graphic 1+2) and Hausdorff distances (HD; graphic 3+4) of white matter (WM) and 
grey matter (GM) per slice. Overlaid boxplots display median values as well as 25th and 75th value percentiles. Grey areas depict the mean standard error 
values ± one standard deviation. 
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Table 3. Table 2. SC GM, WM and TSC accuracy of automatic and semi-automatic segmentations against the manual reference standard segmentations. 
 Parameter GM WM TSC 
AM 
 (on 88% of acquired slices, 
non-discarded from initial 
analysis) 
DSC 0.86 ± 0.04 (0.87) 0.90 ± 0.03 (0.91) 0.95 ± 0.03 (0.95) 
HD (mm) 0.90 ± 0.44 (0.72) 0.82 ± 0.22 (0.75) 0.64 ± 0.27 (0.67) 
SAM  
(on 12% of acquired slices, 
discarded from initial analysis) 
DSC 0.83 ± 0.04 (0.84) 0.96 ± 0.01 (0.96) - 
HD (mm) 1.11 ± 0.55 (0.93) 0.64 ± 0.15 (0.67) - 
AM (on non-discarded samples) 
and SAM (on discarded slices) 
mixed 
(100% of acquired slices) 
DSC 0.86 ± 0.04 (0.86) 0.91 ± 0.04 (0.92) 0.96 ± 0.03 (0.96) 
HD (mm) 0.91 ± 0.46 (0.81) 0.80 ± 0.22 (0.75) 0.60 ± 0.29  (0.55) 
 
Abbreviations: GM=grey matter; WM= white matter cross-section; TSC= spinal cord, AM = automatic segmentations; SAM = semi-automatic segmentation; 
DSC = Dice coefficient; HD = Hausdorff distances 
All values are shown in the form: mean ± standard deviation (median). 
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Discussion 
Visualization of the SC GM in MRI was hampered by technical difficulties until recently 3. Despite 
technological advancements, segmentation of SC compartments remains a challenge 116. In this work, we 
successfully deployed the novel MRI-approach AMIRA and a fully automatic variational segmentation 
algorithm with a shape prior modified for 3D data with a slice similarity prior to demonstrate a fully automated 
approach for segmentation of SC GM and WM.  
In contrast to brain MRI, the environment of the SC presents additional challenges for MRI methods and 
inherently to SC segmentation. Greatest challenges include magnetic field inhomogeneities across the SC, 
cord curvature, shape and size, contact of the SC and the osseous canal, osteophytes causing focal changes in 
CSF flow dynamics within canal, motion artifacts, Gibbs artifacts, partial volume effects, and B1 
inhomogeneity 14–16. The used AMIRA sequence 13 is based on a 2D approach that is, generally, less motion-
sensitive than a 3D sequence. It utilizes a relatively short acquisition time of 51s per slice, which leads to a 
reduction of motion artifacts and is especially suitable for disabled patients with limited abilities in lying still 
(e.g. due to spasticity). The AMIRA approach makes use of a balanced steady state free precession readout, 
which is inherently of low flow sensitivity or "inherently flow compensated". 21The inversion recovery 
preparation is global and non-selective; hence, it does not pose an issue for CSF flow sensitivity either. 
Furthermore, since the SC has a small cross section of roughly 1.3cm by 0.7cm and our slices were located 
close to the isocenter, effects of B1 inhomogeneity do not play a significant role for the present AMIRA 
acquisitions. The even smaller size of the SC GM depicts additional difficulties for MRI methods, requiring 
submillimeter in-plane resolutions, especially for the needs of morphometry. Visualization and segmentation 
of the SC GM and WM is hampered by the similar relaxation times of the two SC compartments limiting the 
use of conventional SC MR-imaging to this matter. Finally, the complex “butterfly” shape of the SC GM 
makes the segmentation of the structure a rather hard task for computer-based segmentation methods. The 
AMIRA approach was able to produce SC images with a high GM/WM contrast in all participants. This was 
achieved in clinically feasible acquisition times (10.2min for a 48mm cervical SC segment). Out of 864 slices, 
only 9 were excluded due to image artifacts mainly resulting from magnetic field inhomogeneities produced 
by bone structures (clavicles, scapulae, humeri, ribs etc.) as well as due to aliasing and motion artifacts. 
Although, these artifacts occurred in a rather small percentage of the acquired images (1%), this should be 
taken into account in future applications of the AMIRA approach.  
A further argument in favor of the use of AMIRA for the purpose of SC GM and WM quantification is the 
fact that our pipeline was able to not only deliver higher accuracy measures compared to a previous study 116 
demonstrating results from various MRI sequences and segmentation algorithms, but also the better accuracy 
performance of an established algorithm on AMIRA compared to T2* MR-images (see also below). This may 
be an indirect indication for superior quality of AMIRA compared to other sequences used so far for spinal 
cord GM and WM quantification. Nevertheless, due to the fact that AMIRA has a non-isotropic resolution, 
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our MRI acquisition may have been more prone to partial volume effects, despite our slices being angulated 
individually in an orthogonal way to the course of the SC.  
The proposed automatic segmentation method showed excellent precision in terms of inter- and intra-session 
reproducibility and was superior to the manual segmentation performed by experienced raters for all SC 
metrics, as measured by both CV and DSC. Our automatic method was also superior in terms of HD for total 
SC, although it did not differ with regard to SC WM and GM. At the same time, accuracy of the automatic 
method was high for total SC, GM and WM, as measured by both DSC and HD. Comparing the present data 
to results of the SC GM segmentation challenge 24, we achieve a superior mean GM DSC of 0.86 vs 0.80 
performed by the “deepseg” algorithm in the SC GM segmentation challenge dataset. This could be potentially 
explained by the high quality of the AMIRA images and/or the use of a multi-center dataset within the 
challenge with results from various MRI sequences and segmentation algorithms. Application of the 
previously published iterative non-local STAPLE algorithm on our AMIRA images showed higher accuracy 
than the original work of Asman et al. 115 (SC GM: median DSC of 0.82 vs 0.75, median HD 1.04mm vs 
2.5mm), which was performed on T2* weighted 3D gradient echo images. While our atlases were constructed 
from a pool of around 800 samples, Asman et al. had around 2000 available slices. Thus, the better accuracy 
seen here can be explained in terms of a possible higher image quality in AMIRA images compared to T2* 
weighted 3D gradient echo images, however a direct comparison of MR sequences within the same subjects 
was not performed. The proposed algorithm's shallow architecture with only a few parameters may make it 
less prone to overfitting to the training set, compared to a state-of-the-art deep neural network. However, a 
direct comparison of our method with the recently presented deep learning methods 117 was not possible in 
this study. 
Precision and accuracy of our automatic method was decreasing in the order total SC→WM→GM. This may 
be caused by the accordingly decreasing size of WM and GM compared to total SC, since small differences 
may be translated into a larger variance. Moreover, the more complex geometry of the GM and WM compared 
to total SC may be more prone to misclassification errors. Finally, despite the good image quality, signal 
contrast was stronger for SC/CSF compared to GM/WM, which in turn could have partly contributed to 
differences in total SC and GM segmentation. Moreover, a slightly lower reproducibility and accuracy of our 
measurements in more caudally acquired slices could also be identified, which may reflect decrease in contrast 
intensity and “noise” increase in AMIRA images acquired closer to the lungs and surrounded by overall greater 
body mass (thorax, shoulders and arms) compared to the more rostral cervical SC.  
Our automatic method also displayed significantly lower intra-session than inter-session variability for all SC 
metrics. However, GM intra- and inter-session CVs were similar with mean values ranging between 4.10–
4.77%. Accordingly, our method demonstrated similar mean intra- and inter-session CVs between 2.54-2.95% 
for WM. We therefore conclude that patient repositioning only slightly influences GM and WM area 
measurements, providing evidence for the suitability of our automatic segmentation method in longitudinal 
settings.  
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In our work, minimal contrast adjustment differences in our manual segmentation led to a marked decrease of 
reproducibility, especially in GM area quantifications, as shown in the manual intra- and inter-rater 
measurements (mean CV up to 19.18%). Since the proposed method is fully automatic and requires no user-
software interaction, it is devoid of additional variation produced by intra- and inter-rater variability. 
Therefore, our method provides significant advantages in big datasets or multi-center studies and as mentioned 
above may also be valuable in the longitudinal evaluation of individual patients (e.g. multiple sclerosis 
patients).  
Compared to the manual reference standard, the automatic method slightly overestimated total SC and WM 
area, while underestimating the GM area. This might be due to different intensity-thresholding in the manual 
segmentation compared to automatic method. The caudal GM area increase shown in Figure 16 can be 
explained by the cervical SC enlargement’s increased volume of motor cells in the GM ventral horns, which 
innervate the upper limb muscles.  
Although a fully automatic segmentation was not feasible on 12% of acquired SC slices, a semi-automatic 
approach with manual total SC segmentation and fully automatic GM and WM segmentation could be 
performed on those slices. This approach also showed high accuracy measurements with mean DSC ≥0.83 in 
both GM and WM. However, compared to the fully automatic method on the initially non-discarded slices, a 
slight accuracy decrease was observed, which could be interpreted in terms of a lower image quality of those 
AMIRA acquisitions. Nevertheless, these results demonstrate a relative robustness of our automatic approach 
even in MR-images of suboptimal quality, which are a rather common phenomenon in clinical routine. 
The present work focuses on SC GM and WM segmentation using AMIRA images of healthy controls. 
Nevertheless, the motivation of our research is to deploy this method in patient data (e.g. multiple sclerosis 
patients) for the development of a potential widely applied MRI biomarker. Exemplary segmentation of 
multiple sclerosis patient data (not shown in detail here) showed that lesion appearance was similar to GM 
and therefore challenged the algorithm where lesions did not respect the GM boundaries (see Figure 19). In 
future work we intend to adjust the current method and/or apply different approaches (e.g. deep learning 
methods 28) to address the current limitations.
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Figure 19. Examples of segmentations of representative multiple sclerosis (MS) patients. Thick continuous line: manual reference standard, dashed line: 
automatic segmentation. A) 54-year old female MS patient. Rostral cervical spinal cord (SC) slices of the C1/C2 level without focal lesions. Automatic 
segmentation highly corresponds to the manual reference standard.  B) 32-year old male MS patient.  Rostral cervical SC slice of the C2 level with a focal 
posterolateral lesion fused with the left posterior grey matter (GM) horn. Automatic segmentation misclassifies the focal lesion as SC GM. C) 33-year old 
female MS patient. Cervical SC slice of the C3/C4 level with a focal posterior lesion fusing with the posterior SC GM horns and the central SC GM 
commissure. Automatic segmentation misclassifies the focal lesion as SC GM and CSF. 
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Conclusion 
In conclusion, the AMIRA sequence presented as a time-efficient and reproducible MR imaging approach 
within the cervical cord. Our fully automatic segmentation method for SC GM and WM demonstrated further 
high reproducibility and accuracy. We were able to show that a shallow algorithm produces state-of-the-art 
GM-WM segmentation results on the AMIRA data. It is therefore suitable in large longitudinal studies 
investigating upper cervical SC volumes. Reproducibility measures of this work could be further used for 
effect size calculations of SC compartment metrics for studies using the same processing approach. In future 
work we will address the use of deep learning approaches, as demonstrated in recent studies 117. 
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3.3. Spinal Cord Volume Loss: A Marker of Disease Progression in Multiple 
Sclerosis 
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Abstract 
Objective: Cross-sectional studies have shown that spinal cord volume (SCV) loss is related to disease 
severity in multiple sclerosis (MS). However, long-term data are lacking. Aim was to evaluate SCV loss as a 
biomarker of disease progression in comparison to other MRI-measurements in a large cohort of relapse-onset 
MS-patients with 6-year follow-up.  
Methods: The upper-cervical SCV, the total brain volume (TBV) and the brain T2 lesion volume (T2LV) 
were measured annually in 231 MS-patients (180 relapsing-remitting (RRMS) and 51 secondary progressive 
(SPMS)) over 6 years on 3D T1-weighted MPRAGE images. Expanded disability status scale (EDSS) and 
relapses were recorded at every follow-up.  
Results: Patients with SPMS had lower baseline SCV (p<0.01), but no accelerated SCV loss compared to 
those with RRMS. Clinical relapses were found to predict SCV loss over time (p<0.05) in RRMS. Further, 
SCV loss, but not TBV and T2LV, was a strong predictor of EDSS worsening over time (p<0.05). The mean 
annual rate of SCV loss was the strongest MRI-predictor for the mean annual EDSS change of both RRMS 
and SPMS separately, while correlating stronger in SPMS. Every 1% increase of the annual SCV loss rate 
was associated with an extra 28% risk-increase of disease progression in the following year in both groups.  
Conclusion: SCV loss over time relates to the number of clinical relapses in RRMS, but does overall not 
differ between RRMS and SPMS. SCV proved to be a strong predictor of physical disability and disease 
progression, indicating that SCV may be a suitable marker for monitoring disease activity and severity. 
 
Abbreviations 
ANCOVA: analysis of covariance  
EDSS: expanded disability status scale 
LMER: linear mixed effects regression  
MLR: multiple linear regression 
MPRAGE: magnetization-prepared rapid gradient-echo images 
MS: multiple sclerosis 
RRMS: relapsing-remitting multiple sclerosis 
SC: spinal cord 
SCV: spinal cord volume 
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SPMS: secondary progressive multiple sclerosis 
TBV: total brain volume 
T1w: T1-weighted 
T2LV: T2 lesion volume 
T25fwt: timed 25-foot walk test 
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Introduction 
Multiple sclerosis (MS) is an inflammatory disease of the brain and the spinal cord (SC) that leads to 
demyelination and neurodegeneration. Atrophy is considered to be the consequence of neurodegeneration in 
MS and can be measured in vivo using magnetic resonance imaging (MRI) as a reduction of central nervous 
tissue volume 88,118–121. 
SC abnormalities have been observed in up to 83% of MS patients, with 60% occurring in the cervical region 
5,77,78. SC lesions are of diagnostic as well as prognostic importance in MS 79. However, previous studies were 
inconsistent regarding the correlation between lesional SC abnormalities and MS-related disability 45,78,88. In 
contrast, SC volume (SCV) or cross-sectional area measurements have indicated a stronger and more 
consistent relationship to disability in MS 5,27,44,45,95,97,121–123. Indeed, SCV loss has been shown to be more 
extensive in progressive forms of the disease 44,94,95. It mainly reflects a diffuse process, which seems at best 
weakly related to focal brain and SC MS lesions 88,90.  
Despite the interest raised by cross-sectional and short-term follow-up volumetric SC studies, there is a lack 
of larger scale longer-term longitudinal studies on SCV loss in MS. This is mainly because the SC is 
infrequently included in imaging protocols, because of cost, time restrictions, technical difficulties in 
acquiring high-quality MR-images and in quantifying SC metrics in a reliable and time-efficient way 3,124. As 
a result, there is a knowledge gap on the dynamic changes of SC measures and their association with the 
patient’s clinical picture over time. 
We hypothesized that SCV loss could be strongly associated with clinical changes over time, contributing 
stronger to disease progression than brain MRI measurements. Aim of this study was to evaluate SCV loss in 
a large cohort of relapsing-onset MS patients, which have been followed over a period of 6 years with annual 
clinical and MRI exams. Our goal was to evaluate SCV loss as a feasible biomarker in MS in comparison to 
brain MRI metrics and assess potential between-group differences in a fast, clinically easy applicable fashion 
using high-resolution brain and not SC scans. 
 
 
Methods 
Study design and participants 
Clinical and MRI data of relapsing-remitting (RR) and secondary-progressive (SP) MS patients of an ongoing 
large scale cohort study 77 (240 relapse onset MS patients in total) from a single centre (MS Center, University 
Hospital, Basel) were analysed. Patients were followed over a maximum of 6 years (7 annual time points). 
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The diagnosis of MS was made in accordance with international panel established criteria 125. The local ethics 
committee approved the study. 
 
Procedures 
All patients underwent a standardized neurological examination including the Expanded Disability Status 
Scale (EDSS; www.neurostatus.org) by trained and certified examiners and timed 25-foot walk test (T25fwt) 
annually. Definite clinical disease progression was defined according to the following conventions: 1a) an 
increase of 1 point in EDSS if the baseline EDSS score was ≤5.5 OR, 1b) an increase of 0.5 point in EDSS if 
the baseline EDSS score was >5.5 AND 2) no relapse in the last 12 months. The number of relapses during 
the 12 months prior to every follow-up was noted with every clinical evaluation, as well as their sum from 
baseline to each follow-up. 
All MRI scans were performed on the same 1.5T Magnetom Avanto MR scanner (Siemens Medical Solutions, 
Erlangen, Germany). Morphological analyses were performed on high-resolution three-dimensional T1-
weighted (T1w) magnetization-prepared rapid gradient-echo (MPRAGE) brain MRI scans acquired in sagittal 
orientation (TR/TI/TE = 2080/1100/3.0 ms; α = 15°, 160 slices, resolution: 0.98x0.98x1 mm3), covering the 
upper cervical SC.  
SCV analysis was performed using an established semi-automatic software (CORDIAL), which allows a fast 
and reliable segmentation and volumetry of the SC with minimal user interaction 46,102. The segmentation was 
carried out over a 35mm long SC segment, starting 27mm below the cisterna pontis, which corresponds 
roughly to the SCV between the Foramen magnum and the C2/C3 intervertebral disc (Figure e-1). 
Segmentations were visually inspected for quality and excluded from further statistical analysis in case of 
segmentation errors.  
Total brain volume (TBV) was computed for each patient from the T1w-images with the fully automated tool 
“Structural Image Evaluation, using Normalization, of Atrophy” for cross-sectional studies (SIENAX version 
2.6) 126. The SIENAX volume-correction factor was used for normalizing the TBV regarding variations of 
head size. All analyses were performed on these corrected volumes. 
All brain white matter lesions (T2LV) were segmented by trained expert observers according to the standard 
operating procedures used at the local institution for the analysis of clinical phase II and phase III trial as 
described before 127. 
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Statistical analysis 
The mean annual SCV loss rate, the mean annual TBV loss rate and the mean rate of annual T2LV increase 
over 6 years was determined for every patient as the average of the annualized changes between all available 
time points. In order to approximate a normal distribution, logarithmic (EDSS) and inverse transformations 
(T25fwt) were performed. The annual EDSS and annual T25fwt changes were calculated based on the 
transformed scores. See Appendix 1 (incl. Figure e-2) for exact calculation formulas of mean annual rates and 
changes. 
Comparisons of baseline demographic factors, clinical measurements and number of follow-ups between 
subtypes were made using Welch’s and Pearson’s chi-squared test with Yate’s continuity correction. Between-
group differences in regard to baseline MRI measures and annual rates were performed using analyses of 
covariance (ANCOVA), while correcting for age, sex and disease duration. 
Hierarchical multiple linear regression (MLR) analyses were performed to investigate the associations 
between annual rates of MRI-metrics and annual changes of clinical scores, in a backwards stepwise fashion. 
Independent variables were entered blockwise keeping the following sequence: first demographics and clinical 
factors, then SCV and finally brain metrics. Baseline MRI and clinical measures were always entered into the 
model as correction factors to the respective annual rates, irrespective of whether they reached levels of 
statistical significance. All other independent variables that did not reach levels of statistical significance were 
not included in the final model. 
Linear mixed effects regression (LMER) analyses were deployed to explore the longitudinal correlations 
between clinical and MRI measures in a forward stepwise fashion, using a “random intercept” and a “random 
slope” to allow for within-subject and between-subject variance. Each factor was tested both for its 
contribution to the fit’s intercept as well as to the fit’s slope. The fit’s intercept corresponds to the average of 
the dependent variable, whereas the fit’s slope to the change of the dependent variable over time. Again, 
independent variables were entered blockwise in the above-mentioned sequence (see MLR). All independent 
variables without statistical significance were excluded from the final model.  
In order to evaluate the prediction capabilities of MRI on disease progression and time-to-disease progression, 
a Cox analysis in a backwards stepwise fashion was performed. In patients showing disease progression the 
annual rates were recalculated for the time period between baseline and time of progression. A 10-fold cross-
validation was performed and the corrected concordance probability index (c-index) was assessed. The 
contribution of each factor in the final model was assessed using the proportion of chi-squared. 
All statistical analyses were performed using R Version 3.2.3 (https://www.r-project.org/). 
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Results 
Out of 1180 available MRI datasets of 240 relapse onset patients, 95 datasets (8%; including the complete 
MRI series of 9 patients) were excluded from further analysis due to segmentation errors or image artefacts. 
This resulted in a total of 231 MS patients analysed (180 RRMS and 51 SPMS), which were followed on 
average over 5.1 ± 1.99 years (Figure e-3). Demographics and basic clinical characteristics are described in 
Table 4. Corrected baseline MRI metrics, annual rates, and between group comparisons are shown in Table 5. 
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Table 4. Demographics and basic clinical characteristics of patients with MS 
 
SD=Standard Deviation; EDSS=Expanded Disability Status Scale; T25fwt=Timed 25-Foot Walk Test; 
RRMS=Relapsing Remitting MS; SPMS=Secondary Progressive MS  
Between-group comparisons were performed using Welch’s two sample t-test and Pearson’s chi-squared 
test with Yate’s continuity correction where appropriate. 
 
Characteristics Overall RRMS SPMS p-value 
Number of patients 231 180 51  
Baseline Age (y)    
<0.001 Mean ± SD 44.7 ± 11.2 41.5 ± 10.1 55.4 ± 7.6 
Range 19 ‒ 67 19 ‒ 65 38 ‒ 67 
Sex (Female/Male) 160 / 71 133 / 47 27 / 24 <0.01 
Baseline Disease Duration (y)    
<0.001 Mean ± SD 13.1 ± 9.2 11.4 ± 8.4 19.1 ± 9.7 
Range 0 ‒ 47 0 ‒ 40 1 ‒ 47 
Baseline EDSS    
<0.001 Median 3.0 2.5 4.5 
Range 0 ‒ 7.5 0 ‒ 7.5 1.5 ‒ 7.5 
Baseline T25fwt z-score    
<0.001 Mean ± SD 0 ± 1 0.26 ± 0.86 -0.98 ± 0.90 
Range -2.69 ‒ 3.90 -2.69 ‒ 3.90 - 2.67 ‒ 1.02 
Number of Follow-ups    
0.38 Mean ± SD 5.10 ± 1.99  5.16 ± 1.99 4.88 ± 2.00 
Range 1 ‒ 7 1 ‒ 7 1 ‒ 7 
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Table 5. Adjusted MRI measures of patients with MS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCV= Spinal Cord Volume; SD=Standard Deviation; TBV= Total Brain Volume; T2LV= Brain T2 Lesion 
Volume; RRMS=Relapsing Remitting MS; SPMS=Secondary Progressive MS 
Baseline SCV, TBV and T2LV were adjusted for age, disease duration and gender. Annual SCV rate, annual 
TBV rate and annual T2LV rate were adjusted for age, disease duration, gender and baseline 
SCV/TBV/T2LV respectively. Adjusted values and significance of difference between RRMS and SPMS were 
obtained through analysis of covariance (ANCOVA). 
MRI measure Overall RRMS SPMS p-value 
Baseline SCV (mm3)    
<0.001 Mean ± SD 2380 ± 167 2416 ± 148 2253 ± 170 
Range 1883 ‒ 2724 2121 ‒ 2724 1883 ‒ 2499 
Annual SCV Rate (%/y)    
0.24 Mean ± SD -0.43 ± 0.20 -0.38 ± 0.17 -0.62 ± 0.17 
Range -0.95 ‒ 0.04 -0.73 ‒ 0.04 -0.95 ‒ (-0.31) 
Baseline TBV (cm3)    
<0.001 Mean ± SD 1489 ± 52 1498 ± 46 1433 ± 40 
Range 1340 ‒ 1595 1355 ‒ 1595 1340 ‒ 1543 
Annual TBV Rate (%/y)    
0.41 Mean ± SD -0.43 ± 0.12 -0.41 ± 0.11 -0.50 ± 0.13 
Range -0.75 ‒ (-0.17) -0.69 ‒ (-0.17) -0.75 ‒ 0.17 
Baseline T2LV (mm3)    
0.18 Mean ± SD 6287 ± 1720 5959 ± 1515 7437 ± 1910 
Range 2647 ‒ 12340 2647 ‒ 10250 7437 ‒ 12340 
Annual T2LV rate (%/y)    
<0.05 Mean ± SD 3.48 ± 2.53 4.34 ± 1.95 0.41 ± 1.91 
Range -4.86 ‒ 8.07 -2.90 ‒ 8.07 -4.86 ‒ 4.61 
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SCV changes  
In a first series of statistical analyses, SCV and its change over time was evaluated with respect to 
demographic, clinical and brain MRI metrics using LMER. The analyses revealed that men had larger average 
volumes than females (Males: B= 289, p<0.001), and a significantly faster SCV loss over time (Males: B= -
6.24, p<0.01). Age (B= 3.36, p<0.01) and disease duration (B= -7.94, p<0.001) correlated with the average 
SCV but not with the SCV loss over time. Moreover, TBV (B= 6 x 10-4, p<0.001) and T2LV (B= 2 x 10-3, 
p<0.05) correlated with the average SCV, but not with the SCV loss over time. SPMS on average had lower 
SC volumes (SPMS: B= -175, p<0.01) than RRMS but not an accelerated SCV loss over time. Overall, the 
full model accounted for 98.7% of SCV variance, while the fixed effects alone accounted for 32.7%.  
The sum of clinical relapses in RRMS patients was associated with SCV loss over time (B= -1.06, p<0.05), 
but not with the average SCV. Disease duration (B= -9.58, p<0.001) was associated with the average SCV but 
not with the SCV loss over time. Age did not correlate with the SCV. The final model accounted for 98.7% 
of SCV variance, while the fixed effects alone accounted for 22.3% of the SCV variance. 
 
SCV changes and disability  
In a second step, we were interested in whether measures of disability (EDSS and T25fwt) are associated with 
SCV and brain MRI metrics and their changes over time.  
 
EDSS 
In the LMER analyses, SCV was inversely associated with the average EDSS (B= -4 x 10-4, p<0.001) and the 
EDSS worsening over time (B= 2.1 x 10-5, p<0.05). TBV and T2LV were also correlated with the average 
EDSS (B= -2.2 x 10-7, p<0.05; B= 8.8 x 10-6, p<0.001 respectively), but not with the EDSS worsening over 
time. Finally, sex (Males: B= 0.13, p<0.05), age (B= 5.6 x 10-3, p<0.001), disease duration (B= 2.8 x 10-3, 
p<0.01), and disease subtype (SPMS: B= 0.35, p<0.001) correlated with the average EDSS, but not with the 
EDSS worsening over time. The final model accounted for 87.7% of EDSS variance, while the fixed effects 
alone accounted for 42.6%.  
 
Separate MLR analyses were performed to specifically investigate the extent of correlation between EDSS 
and SCV in each disease type. In RRMS the annual SC rate was the only predictive MRI factor, while age and 
baseline EDSS contributed significantly. The final model demonstrated a weak prediction of the annual EDSS 
change variance, with an adjusted-R2 of 19.2%. Similar to RRMS the annual SC rate was the most important 
predicting factor for the annual EDSS change in SPMS, while again age and baseline EDSS also contributed 
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significantly. The final model demonstrated, however, a moderate prediction of the annual change in EDSS, 
with an adjusted-R2 of 53.8%. The models are described in detail in Table 6. 
 
 
 Spinal Cord Volume Quantification And Clinical Application In Multiple Sclerosis – C. Tsagkas 
 
70 
 
Table 6. Multivariate analysis of clinical measures by disease type. 
Group Final Model Variable β p-value ΔR2 
R
R
M
S
 
Annual EDSS change ~ Age + Baseline EDSS + Baseline 
SCV + Annual SCV Rate 
Adj-R2=19.19% 
P<0.001 
Age 0.25 <0.001 
17.38%, p<0.001 
Sex  - n.s. 
Disease Duration - n.s. 
Baseline EDSS -0.51 <0.001 
Baseline SCV -0.10 n.s. 
Annual SCV Rate -0.16 <0.05 1.81%, p<0.05 
Baseline TBV - n.s. - 
Annual TBV Rate - n.s. - 
Baseline T2LV - n.s. - 
Annual T2LV Rate - n.s. - 
Annual T25fwt change ~ Baseline T25fwt + Baseline SCV + 
Annual SCV Rate + Baseline TBV 
Adj-R2=13.87% 
P<0.001 
Age - n.s. 
0.33%, p=0.23 
Sex - n.s. 
Disease Duration - n.s. 
Baseline T25fwt -0.08 n.s. 
Baseline SCV 0.07 n.s. 
Annual SCV Rate 0.35 <0.001 11.51%, p<0.001 
Baseline TBV 0.18 <0.05 2.03%, p<0.05 
Annual TBV Rate - n.s. - 
Baseline T2LV - n.s. - 
Annual T2LV Rate - n.s. - 
S P M S
 
Age -0.27   <0.05 18.25%, p<0.001 
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SCV=Spinal Cord Volume, TBV=Total Brain Volume, T2LV=Brain T2 Lesion Volume; EDSS=Expanded Disability Status Scale; T25fwt=Timed 25-Foot Walk 
Test; RRMS=Relapsing Remitting MS, SPMS=Secondary Progressive MS; Β=Standardised Regression Coefficients; ΔR2=Adjusted R-Squared Difference; 
N.S.=Not Significant 
 
Annual EDSS change ~ Age + Baseline EDSS + Baseline 
SCV + Annual SCV Rate 
Adj-R2= 53.83 % 
P<0.001 
Sex - n.s. 
Disease Duration - n.s. 
Baseline EDSS -0.23 <0.05 
Baseline SCV 0.03 n.s. 
Annual SCV Rate -0.60 <0.001 35.58%, p<0.001 
Baseline TBV - - - 
Annual TBV Rate - - - 
Baseline T2LV - - - 
Annual T2LV Rate - - - 
Annual T25fwt change ~ Baseline T25fwt + Baseline SCV + 
Annual SCV Rate 
Adj-R2= 49.89 % 
P<0.001 
Age - n.s. 
8.38%, p<0.01 
Sex - n.s. 
Disease Duration - n.s. 
Baseline T25fwt 0.06 n.s. 
Baseline SCV -0.26 <0.05 
Annual SCV Rate 0.65 <0.001 41.51%, p<0.001 
Baseline TBV - n.s. - 
Annual TBV Rate - n.s. - 
Baseline T2LV - n.s. - 
Annual T2LV Rate - n.s. - 
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Timed 25 foot walk test 
In the LMER analyses, SCV as well as TBV was inversely associated with the average T25fwt (B= 3.7 x 10-
5, p<0.001; B= 6.8 x 10-8, p<0.01 respectively), but not with its worsening over time. T2LV correlated with 
both, the average T25fwt (B= -1.4 x 10-6, p<0.01) and its worsening over time (B= -2.2 x 10-7, p<0.05). Age 
(B= -1 x 10-3, p<0.001), disease duration (B= -6.2 x 10-4, p<0.001), and disease subtype (SPMS: B= -5.7 x 10-
2, p<0.001), but not sex, correlated with the average T25fwt. Only sex (Males: B= - 2.9 x 10-3, p<0.01) and 
disease type (SPMS: B= -4.5 x 10-3, p<0.05) correlated with the T25fwt worsening over time. The final model 
accounted for 94.2%, while the fixed effects alone accounted for 40% of the T25fwt variance. 
 
Separate MLR analyses were performed to specifically investigate the extent of correlation between T25fwt 
and SCV in each disease type. In the RRMS group, the annual SC rate was the most important predicting 
factor, while baseline TBV also contributed significantly. The final model demonstrated a weak prediction of 
the annual T25fwt change variance, with an adjusted-R2 of 13.9%. In terms of the annual T25fwt changes in 
SPMS patients, the annual SC rate was the most important predicting factor, while baseline SCV also 
contributed significantly. The final model demonstrated a moderate prediction of the annual change in T25fwt, 
with an adjusted-R2 of 49.9%. The models are described in detail in Table 6.  
 
Prediction of disease progression 
Last, the predictive capabilities of MRI metrics on disease progression and time-to-disease progression were 
evaluated. A Cox analysis showed that disease type, baseline EDSS, annual rate of SCV loss and baseline 
TBV were significant predictors of disease progression. The annual rate of SCV loss explained 34% of the 
final model’s chi-squared and was the strongest MRI measure. Its hazard ratio was 0.72 (95% confidence 
interval [CI]: 0.61 ‒ 0.84, p<0.001). Every 1% increase of the annual rate of SCV loss was associated with an 
extra 28% risk increase to develop disease progression in the following year. The c-index resulting from a 10-
fold cross validation of the cohort was 70%, showing a moderate predictive power of the model. Details are 
displayed in Table 7. 
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Table 7. Cox analysis of Disease Progression 
 
 
 
 
 
 
 
 
 
 
 
 
 
aSCVLR=annualised SC volume loss rate; B=regression coefficients; HR=Hazard Ratios; 95% CI=95% Confidence Intervals; c-index=10-fold 
crossvalidation corrected concordance probability index; n.s.=Not Significant 
 
Final Model Variable HR  (95% CI) 
Proportion of 
Chi-Square 
p-value 
(Disease Progression, Time to 
Disease Progression) ~ Disease 
Type +Baseline EDSS + Baseline 
SCV + Annual SCV Rate + 
Baseline TBV 
 
Concordance=0.717 (se=0.04) 
Wald test=51.53, p<0.001 
Score (logrank) test=54.16, 
p<0.001 
Total Chi-Square=51.54, p<0.001 
C-Index=0.70 
Age - - - n.s. 
Sex - - - n.s. 
Disease Duration - - - n.s. 
Disease Type 
(SPMS) 
4.62 2.46 - 8.67 43.9% <0.001 
Baseline EDSS 0.29 0.15 - 0.58 24.3% <0.001 
Baseline SCV 1.0008 1.0 - 1.002 6.7% n.s. 
Annual SCV Rate 0.72 0.61 – 0.84 34% <0.001 
Baseline TBV 1.0000 1.0000 – 1.0000 18% <0.01 
Annual TBV Rate - - - n.s. 
Baseline T2LV - - - n.s. 
Annual T2LV - - - n.s. 
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Discussion 
This study is the first longitudinal longer-term analysis of SCV loss in MS investigating the upper cervical 
SCV in a large cohort of patients with relapse-onset MS for up to 6 years of follow-up. The temporal profile 
of SC tissue loss is illustrated with its association to clinical changes and its potential to monitor the clinical 
course of the disease. For that purpose we deployed a fast, clinically easy applicable pipeline using high-
resolution brain scans. 
The SC segmentation was performed in a mainly automatic fashion with minimal user interaction, thus 
avoiding bias from manual segmentations or manual corrections. Our approach using the upper cervical SCV 
instead of the upper SC area is thought to be less susceptible to possible bias from focal atrophy due to lesions 
and possesses high test-retest reliability 102. 
In line with previous cross-sectional studies 27,44,45,94,95,97,118,121–123, patients with SPMS had lower SCV 
compared to RRMS. However, there was no evidence of accelerated SCV loss over time in SPMS compared 
with RRMS. The observed between-group differences in cross-sectional settings can be explained by longer 
disease duration and higher age of the SPMS patients (Figure 20), arguing against a theoretical preferential 
SCV loss in this group as suggested by previous smaller scale and shorter duration studies 27,44,45,94,95,97,118,121–
123. Similar findings were present regarding TBV loss when compared between groups in the present cohort. 
This is in line with a large study by De Stefano et al. showing that there is no difference in the rate of brain 
volume loss in earlier versus more advanced MS phenotypes on a group level 119. Overall, these results indicate 
that the rate of tissue loss in the central nervous system is in general comparable in relapse-onset MS 
phenotypes. 
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Figure 20. SCV and its change over time separated by disease type: RRMS (red) and SPMS (turquoise) patients.  
(A) The fine lines represent the raw measurements of SCV for each patient over 6 years of follow-up, while the thicker blue lines depict the respective “trends” 
of SC volume loss in the two disease types. Notice, that despite a significant difference of SCV at baseline (B), the annual SCV rate did not differ significantly 
between disease types, after adjusting for age, sex and disease duration (C). The error bars (whiskers) represent the mean +/- the standard deviation. 
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In terms of T2LV, RRMS patients showed faster accumulation of T2LV, reflecting the inflammatory activity 
dominating in this phase of the disease. However, SCV loss over time seemed to be largely independent of 
change in TBV and T2LV.  
As expected, men had larger SCV at baseline, however, exhibited more pronounced SCV loss over time, which 
is in line with the clinical observation that male sex is an indicator of poorer prognosis 128. Yet, our statistical 
analyses predicting the EDSS and disease progression could not confirm a faster clinical worsening of male 
patients compared to females. This may be explained by the follow up span which might not have been long 
enough. Neither age nor disease duration seemed to have an effect on SCV loss over time, suggesting a 
relatively steady SC tissue loss in both patient groups.  
In RRMS, an increased cumulative number of clinical relapses was associated with faster SCV loss over time. 
One may speculate that with every new clinical relapse in a RRMS patient, some degenerative cascade is 
activated accelerating SCV loss, an effect that seems to persist way beyond the initial acute inflammatory 
phase of the relapse. The data further suggest that the accumulation of clinical relapses shapes - at least 
partially - a patient’s profile in terms of SCV loss. It also implies that the reduction of clinical relapses -which 
constitutes a fundamental therapeutic strategy of RRMS - should beneficially affect this process 129. In the 
LMER, SCV proved to be the only MRI metric to strongly explain the clinical progression over time as 
measured by speed of EDSS worsening for the whole cohort. TBV and T2LV were associated with the average 
patients’ disability, but did not independently relate to EDSS worsening over time, when added to a statistical 
model that included SCV. Regarding the T25fwt, SCV and TBV correlated with the patients walking speed 
although they failed to correlate with its worsening over time. Instead, the T2LV was a predictor of these 
changes, probably driven by the RRMS group. 
Regardless of a similar SCV loss pace in both patient groups, association of the annual rate of SCV loss with 
clinical scores was remarkably higher for patients with SPMS than for the RRMS group in all analyses. This 
shows that despite the assumption of same underlying causal pathomechanisms 83,129, the clinical impact in 
SPMS is more pronounced. This can be explained by higher age and accumulation of damage over time in 
SPMS patients, entailing chronic immune activation, increased oxidative stress-related damage, loss of trophic 
support and exhaustion of repair and compensatory mechanisms 83,84. This allows axonal and myelin damage 
to be “translated” in a much more straightforward way into clinical deficits once the threshold of neuronal 
injury and/or repair has been exceeded. On the other hand, it is possible to hypothesize that RRMS patients 
still have sufficient reserves of cortical adaptation, remyelination, axonal repair and neuroprotection, which 
allow them on one hand to maintain or re-establish the functionality of neuronal tissue and on the other hand 
“mask” the produced axonal loss through neuroplasticity occurring at higher cortical centres 237,265,266. 
Considering that, in future works additional measures of neuroprotective mechanisms such as quantitative 
MRI measurements (e.g. magnetization transfer imaging, diffusion tensor imaging, and proton magnetic 
resonance spectroscopy) may shed light into this interesting aspect of the disease 83,130,131. The annual SCV 
loss rate was to a great extent the only MRI factor in predicting clinical worsening, while the annual TBV and 
 Spinal Cord Volume Quantification And Clinical Application In Multiple Sclerosis – C. Tsagkas 
 
77 
 
T2LV did not significantly contribute. Predicting disease progression using a cox analysis, it was shown that 
the annual rate of SCV loss was the strongest MRI measure and a 1% rate increase was associated with a 28% 
risk increase to develop disease progression in the following year. Further SPMS patients were shown to be 
more susceptible to disease progression. This is also adding to the evidence that SCV could possibly be a 
better disease marker compared to brain volume loss and lesion load in the brain. 
This study has a number of limitations. It aimed to analyse follow-up data of a group of patients with MS in a 
retrospective fashion. Some patients were lost to follow-up during the study, leading to incomplete data sets 
and potential bias. While the SPMS patient group was smaller than the RRMS, the two groups were followed-
up for a similar amount of time. The latter at least does not support a preferential loss of patients with 
progression. Furthermore, the lack of a representative control group of healthy subjects made it impossible to 
assess MS-related SC volume loss as compared to SCV decline due to normal aging. However, it is likely that 
the observed SCV loss is mainly a disease-related effect, as in the normal population the degree of SCV loss 
seems to be smaller 103. Unfortunately, no study has so far assessed the effect of age on SCV loss in healthy 
controls longitudinally. In this study, the potential effect of disease modifying drugs (DMD’s) on 
inflammation, and ultimately on SCV variation was not included in our analysis. In our cohort 68% of patients 
were treated with DMD’s at baseline including primarily first line injectables (63%). While injectables also 
show an effect on brain atrophy we believe that this effect is rather negligible 132. Finally, since the study had 
no T2w sequence covering the area of volume measurement over all time points analysed here, the impact of 
SC lesions was not assessed. 
 
In conclusion, this study indicates that the measurement of SCV loss represents a reliable imaging marker for 
the monitoring of disease activity and progression in MS. SCV loss was shown to be directly affected by 
inflammatory events (relapses), supporting at least a partial role of inflammation in driving neurodegeneration 
in MS. Finally, the study provides evidence of a dissociation in the clinical consequences of SC volume loss 
in RRMS versus SPMS. That said, SCV could be a useful endpoint in clinical trials of therapeutic agents that 
are aiming at the degenerative process in MS, a much wanted unmet need. 
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Supplementary Material 
Appendix 1 
The annualized percentage changes (APC) in the volume (V) of the spinal cord, the total brain mass, and the 
T2-weighted lesions were calculated for every patient (x) with n available follow ups at given time points [t1, 
t2, …, tn] (in years) with corresponding fractional annual time intervals ∆ti ∶= ti+1 – ti (for i = 1, 2, …, n – 1) 
using 
 
𝑉𝐴𝑃𝐶
(𝑥)
(𝑖) ∶=
𝑉(𝑥)(𝑡𝑖+1)/𝑉
(𝑥)(𝑡𝑖) − 1
∆𝑡𝑖
× 100  
       
and subsequently the patient’s mean annualized percentage volume change  
〈𝑉𝐴𝑃𝐶
(𝑥)〉 =  
1
𝑛 − 1
∑ 𝑉𝐴𝑃𝐶
(𝑥)
(𝑖)
𝑛−1
𝑖=1
 
 
In complete analogy, the annualized changes (AC) of the logarithmically-scaled expanded disability status 
scale (EDSS) and the inversely-scaled timed 25-foot walk test (T25fwt) were derived using  
𝐸𝐷𝑆𝑆𝐴𝐶
(𝑥)(𝑖) ∶=
𝐸𝐷𝑆𝑆(𝑥)(𝑡𝑖+1) − 𝐸𝐷𝑆𝑆
(𝑥)(𝑡𝑖)
∆𝑡𝑖
  
𝑇25𝑓𝑤𝑡𝐴𝐶
(𝑥)(𝑖) ∶=
𝑇25𝑓𝑤𝑡(𝑥)(𝑡𝑖+1) − 𝑇25𝑓𝑤𝑡
(𝑥)(𝑡𝑖)
∆𝑡𝑖
  
and subsequently the patient’s EDSS and T25fwt mean annualized change  
〈𝐸𝐷𝑆𝑆𝐴𝐶
(𝑥)〉 =  
1
𝑛 − 1
∑ 𝐸𝐷𝑆𝑆𝐴𝐶
(𝑥)
(𝑖)
𝑛−1
𝑖=1
 
〈𝑇25𝑓𝑤𝑡𝐴𝐶
(𝑥)〉 =  
1
𝑛 − 1
∑ 𝑇25𝑓𝑤𝑡𝐴𝐶
(𝑥)
(𝑖)
𝑛−1
𝑖=1
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Figure e-1. Cervical cord segmentation using CORDIAL. Display of the fine-segmentation in red in axial 
(left), sagittal (middle) and coronal view (right). The spinal cord volume is measured between the blue lines. 
 
Figure e-2. Segmented MR images of one representative RRMS patient. The blue lines on each image depict 
the segmented volume, which corresponds to the upper cervical cord between the foramen magnum and the 
C2/C3 intervertebral disc. The mean annual SCV loss rate for each patient was calculated using the 
subsequent SC volume values from a follow-up to the next. 
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Figure e-3.  Number of patients participating in each follow-up. RRMS: relapsing remitting MS; SPMS; 
secondary progressive MS. 
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Abstract 
 
Background: Little is known on longer-term changes of spinal cord volume (SCV) in primary progressive 
multiple sclerosis (PPMS). 
Objective: Longitudinal evaluation of SCV loss in PPMS and its correlation to clinical outcomes, compared 
to relapse-onset MS subtypes. 
Methods: A total of 60 MS age-, sex- and disease duration-matched patients (12 PPMS, each 24 relapsing-
remitting (RRMS) and secondary progressive MS (SPMS)) were analysed annually over 6 years of follow-up. 
The upper cervical SCV was measured on 3D T1-weighted MPRAGE images using a semi-automatic software 
(CORDIAL), along with the total brain volume (TBV), brain T2 lesion volume (T2LV)  and Expanded 
Disability Status Scale (EDSS).  
Results: PPMS showed faster SCV loss over time than RRMS (p<0.01) and by trend (p=0.066) compared to 
SPMS. In contrast to relapse-onset MS, in PPMS SCV loss progressed independently of TBV and T2LV 
changes. Moreover, in PPMS, SCV was the only MRI measurement associated with EDSS increase over time 
(p<0.01), as opposed to RRMS and SPMS.  
Conclusions: SCV loss is a strong predictor of clinical outcomes in PPMS and was shown to be faster and 
independent of brain MRI metrics when compared to relapse-onset MS. 
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Introduction 
Primary progressive multiple sclerosis (PPMS) is clinically characterised by sustained neurologic disability 
progression without early relapses or remissions 125. Other distinctive features are an older onset age, a 
relatively equal sex incidence and the most common presentation being a progressive paraparesis rather than 
visual or sensory disturbances 133. The spinal cord (SC) is therefore an important locus of pathology in PPMS, 
with a frequent occurrence of SC lesions and diffuse SC abnormalities, even in the very onset of the disease 
125,134,135.  
In contrast to brain magnetic resonance imaging (MRI) metrics, studies have shown a strong clinico-
radiological correlation between SC atrophy measurements and clinical disability at all stages of the disease 
44,45,134,136–139. In a recent study SC atrophy together with the number of asymptomatic SC lesions predicted 
the development of MS disability 5 years after a non-spinal clinical isolated syndrome 80. SC atrophy was 
further found to be an early distinctive feature between relapsing and progressive disease types (in cross-
sectional analyses), predominantly seen in the grey matter, and being more pronounced in progressive MS 
with superior correlation to clinical disability compared to brain MRI measures 95,140.4 Reduction of SC cross-
sectional area was found to occur largely independent from brain atrophy and lesion load in PPMS 
5,44,134,136,138,140,141. Qualitative MRI studies demonstrate irreversible axonal injury and reactive gliosis in the 
SC of PPMS 142 and even in absence of extensive SC atrophy, the structural integrity of neurons, demyelination 
and abnormalities in the glutamatergic pathways in the cervical cord of early PPMS show strong associations 
with physical disability 118.  
Former studies demonstrate controversial results concerning between-group differences not only in cross-
sectional but also short-term longitudinal SC atrophy assessments. While Lukas et al. 44 could not differentiate 
disease types by 24-month SC atrophy rates, Cawley et al. 143 demonstrated a significant reduction of cervical 
cross-sectional area over 1 year in PPMS over secondary progressive MS (SPMS) patients suggesting SC 
atrophy as a suitable marker for clinical trials. Others, however, showed also an evident reduction of cervical 
cross-sectional area in the very onset of SPMS, showing a great need for more data supporting the role of 
spinal cord damage in PPMS 144.  
The aim of this study was to analyse long-term changes of spinal cord volume over 6 years with focus on 
primary progressive MS in comparison to matched relapse-onset MS patients. We hypothesized that in PPMS 
the upper cervical cord volume would be the predilection site of volume loss over time when compared to 
whole brain and brain lesion volumes. Further the relationship between MRI measures and physical disability 
were investigated in a longitudinal fashion. 
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Methods 
Study design and participants 
Clinical and MRI data of 6 years of follow-up (7 annual time points) of 12 PPMS, 24 RRMS, and 24 secondary 
progressive (SP) MS patients of an ongoing large scale cohort study 77 (incl. 253 MS patients in total) from a 
single centre (MS Centre, University Hospital, Basel) were selected retrospectively. Selection of patients was 
based on propensity score matching, as described in the statistical analysis section. Patients’ diagnosis of MS 
was made in accordance with international panel established criteria 125. The local ethics committee approved 
the study. 
 
Procedures 
All patients received annual standardized neurological examination including the Expanded Disability Status 
Scale (EDSS; www.neurostatus.org) and timed 25-foot walk test (T25fwt). 
All MRI scans were performed on a single 1.5 T Magnetom Avanto MR scanner (Siemens Medical Solutions, 
Erlangen, Germany). Morphological analyses were performed on high-resolution three-dimensional T1-
weighted (T1w) magnetization-prepared rapid gradient-echo images (MPRAGE) brain scans acquired in 
sagittal plane (TR/TI/TE = 2080/1100/3.0 ms; flip angle = 15°, 160 slices, resolution: 0.98x0.98x1mm3), 
covering the upper cervical SC.  
SC volume (SCV) was estimated using an established semi-automatic software (CORDIAL), which allows a 
fast and reliable segmentation and volumetry of the spinal cord with minimal user interaction 46,102. The 
segmentation was carried out over a 35mm long SC segment, starting 27mm below the cisterna pontis, which 
corresponds roughly to the SC volume between the Foramen magnum and the C2/C3 intervertebral disc 
(Figure 21). Segmentations were visually inspected for quality and excluded from further statistical analysis 
in case of segmentation errors. 
 
Figure 21. In the pre-segmentation step (left), the user selects manually a subset of voxels belonging to the 
SC (green) versus background (e.g., cerebrospinal fluid, vertebral bodies; red) and additionally an 
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anatomical landmark at the medullopontine sulcus (red dot). Subsequently, the segmentation (middle) is 
performed in a fully automatic fashion (yellow). In a last step (right), a volume is calculated in a defined 
distance of the anatomical landmark. For details see also Amann et al. 2016. 
 
Total brain volume (TBV) was computed for each patient from the T1w images with the fully automated tool 
“Structural Image Evaluation, using Normalization, of Atrophy” for cross-sectional studies (SIENAX version 
2.6) 126. The SIENAX volume-correction factor was used for normalizing the TBV regarding variations of 
head size. All analyses were performed on these corrected volumes. 
All brain white matter lesions (T2LV) were segmented by trained experts according to the standard operating 
procedures used at the local institution for the analysis of clinical phase II and phase III trials as described 
before 127.  
 
Statistical analysis 
Baseline covariates, including gender, age and disease duration, were used to calculate propensity scores for 
each individual patient. These propensity scores were derived from a logistic regression model, in which the 
primary progressive disease type was the outcome variable and baseline characteristics formed the explanatory 
variables. RRMS and SPMS were matched with PPMS patients, based on high similarity of propensity scores, 
on a 2:1 basis for each group. Success of matching was assessed using analysis of variance (ANOVA) and 
post hoc analyses using Bonferroni correction. All further statistical analyses were performed on the matched 
data. 
Mean annual SCV loss rate, mean annual TBV loss rate and mean annual T2LV change rate over 6 years were 
determined for every patient as the average change between all available time points. In order to approximate 
a normal distribution, logarithmic (EDSS) and inverse transformations (T25fwt) were performed. 
Comparisons of baseline demographics, clinical measurements and number of follow-ups between subtypes 
were made using Welch’s Two Sample t-Tests and Pearson’s Chi-squared test with Yate’s continuity 
correction. Between-group differences in regard to baseline MRI measures and annual rates were performed 
using analyses of covariance (ANCOVA), while correcting for age, sex and disease duration. 
Linear mixed effect regression (LMER) analyses were deployed to explore the longitudinal associations 
between clinical and MRI measures in a forward stepwise fashion, using a “random intercept” and a “random 
slope” to allow for within-subject and between-subject variance. Each variable was tested both for its 
contribution to the fits’ intercept as well as to the fits’ slope. In all regression LMER analyses with a clinical 
measurement as outcome, the independent variables were evaluated in four blocks (demographics and clinical 
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factors-TBV-SCV-T2LV). Multiple comparisons in post hoc analyses were performed using Bonferroni 
correction. 
All statistical analyses were performed using R Version 3.2.3 (https://www.r-project.org/). 
 
Results 
Out of 253 MS patients (12 PPMS, 180 RRMS, 51 SPMS), 60 patients (all 12 PPMS, 24 RRMS, 24 SPMS) 
were included in the study after propensity score matching of the RRMS and SPMS to the PPMS patients. 
The selected cohort was monitored for a mean number of 5.15 ± 1.91 annual follow-ups (Figure 22). Out of 
304 available MRI datasets, 26 (9%) were excluded from further analysis due to segmentation or image 
artefacts. These exclusions were evenly distributed among different disease types of our cohort; none of the 
selected patients had to be fully excluded. Baseline demographics and clinical characteristics are described in 
Table 8. Corrected baseline MRI metrics, annual rates, and between-group comparisons are displayed in Table 
9 and Figure 23. 
 
Figure 22. Number of patients participating in each follow-up. RRMS: relapsing remitting MS; SPMS: 
secondary progressive MS; PPMS: primary progressive MS.
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Table 8. Demographics and basic clinical characteristics of patients with MS 
 
SD=Standard Deviation; EDSS=Expanded Disability Status Scale; T25fwt=Timed 25-Foot Walk Test; 
PPMS=Primary Progressive MS; RRMS=Relapsing Remitting MS; SPMS=Secondary Progressive MS;  
n.s.=not significant for any comparisons between PPMS, RRMS and SPMS  
PPMS versus RRMS: † ≤ 0.05, †† ≤ 0.01, ††† ≤ 0.001. 
PPMS versus SPMS: ‡ ≤ 0.05, ‡‡ ≤ 0.01, ‡‡‡ ≤ 0.001. 
Characteristics Overall PPMS RRMS SPMS p-value 
Number of patients 60 12 24 24  
Baseline Age (y)     
n.s. Mean ± SD 48.9 ± 8.2 46.7 ± 6.6 48.2 ± 9.6 50.6 ± 7.4 
Range 34 – 65 34 – 58 34 – 65 38 – 64 
Sex (Female/Male) 32 / 28 6 / 6 15 / 9 11 / 13 n.s. 
Baseline Disease Duration 
(y) 
 
 
  
n.s. 
Mean ± SD 10.2 ± 6.6 8.6 ± 7.1 8.9 ± 5.9 12.3 ± 6.6 
Range 1 – 27 1 – 27 2 – 20 1 – 25 
Baseline EDSS     
***, ††† Median 3.5 4.625 2.25 4.0 
Range 0 – 7.5 2.5 – 7.5 0 – 4.0 1.5 – 7.5 
Baseline T25fwt z-score     
** Mean ± SD 0 ± 1 -0.22 ± 1.24 0.52 ± 0.74 -0.44 ± 0.90 
Range -2.07 – 1.74 -2.07 – 1.74 -0.61 – 1.68 -2.07 – 1.28 
Number of Follow-ups     
n.s. Mean ± SD 5.15 ± 1.91 5.25 ± 1.48 5.33 ± 2.04 4.92 ± 2.02 
Range 1 – 7 2 – 7 1 – 7 2 – 7 
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RRMS versus SPMS: * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001. 
Between-group comparisons were performed using Welch’s two sample t-test and Pearson’s chi-squared 
test with Yate’s continuity correction where appropriate. 
 
Table 9. Corrected MRI measures of patients with MS 
MRI measure Overall PPMS RRMS SPMS p-value 
Baseline SCV (mm3)     
n.s. 
(RRMS vs PPMS: 
0.08) 
Mean ± SD 2379 ± 144 2247 ± 116 2465 ± 110 2359 ± 133 
Range 2108 – 2655 2108 – 2435 2308 – 2655 2133 – 2565 
Annual SCV Rate (%)     
† Mean ± SD -0.91 ± 0.64 -1.89 ± 0.34 -0.35 ± 0.33 -0.98 ± 0.27 
Range -2.38 – 0.28 -2.38 – (-1.1) -0.78 – 0.33 -1.58 – (-0.55) 
Baseline TBV (cm3)     
n.s. Mean ± SD 1468 ± 46 1473 ± 43 1483 ± 46 1451 ± 42 
Range 1378 – 1562 1378 – 1535 1390 – 1562 1396 – 1561 
Annual TBV Rate (%)     
n.s. Mean ± SD -0.45 ± 0.18 -0.44 ± 0.14 -0.33 ± 0.12 -0.56 ± 0.18 
Range -0.85 – (-0.05) -0.62 – (-0.15) -0.54 – (-0.05) -0.85 – (-0.21) 
Baseline T2LV (mm3)     
n.s. Mean ± SD 6121 ±  3618 5514 ± 3686 4852 ± 3184 7693 ± 3534 
Range 590 – 15270 1894 – 15270 1091 – 11800 590 – 14480 
Annual T2LV rate (%)     
n.s. Mean ± SD 1.66 ± 0.84 2.14 ± 0.62 1.97 ± 0.66 1.13 ± 0.83 
Range -0.32 – 3.21 1.21 – 3.21 0.79 – 3.04 -0.32 – 2.68 
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SCV= Spinal Cord Volume; SD=Standard Deviation; TBV= Total Brain Volume; T2LV= Brain T2 Lesion 
Volume; PPMS=Primary Progressive MS; RRMS=Relapsing Remitting MS; SPMS=Secondary Progressive 
MS;  
n.s.=not significant for any comparisons between PPMS, RRMS and SPMS  
PPMS versus RRMS: † ≤ 0.05, †† ≤ 0.01, ††† ≤ 0.001. 
PPMS versus SPMS: ‡ ≤ 0.05, ‡‡ ≤ 0.01, ‡‡‡ ≤ 0.001. 
RRMS versus SPMS: * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001. 
Baseline SCV, TBV and T2LV were corrected for age, disease duration and sex. Annual SCV rate, annual 
TBV rate and annual T2LV rate were corrected for age, disease duration, sex and baseline SCV/TBV/T2LV 
respectively. Corrected values and significance of difference between RRMS and SPMS were obtained 
through analysis of covariance (ANCOVA). 
 
 
Figure 23. SCV display comparing RRMS (red), SPMS (green) and PPMS (blue) patients. A) At baseline, 
SCV was not significantly different between groups but B) the annual SCV rate was significantly higher for 
the PPMS when compared to the RRMS (p<0.05). RRMS and SPMS as well as SPMS and PPMS did not differ 
significantly in terms of annual SCV rate. 
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Between-group differences in MRI measures 
In the LMER analyses PPMS had lower SCV on average, as well as a faster SCV loss over time, when 
compared with RRMS patients (Figure 24). PPMS had also by trend faster SCV loss over time compared to 
the SPMS patients. Furthermore, male sex was significantly correlated with a higher SCV average.  
No significant differences were demonstrated between groups in terms of TBV and T2LV. The statistical 
models are exhibited in detail in Table 9. 
Figure 24. Segmented MR imaging of one representative PPMS patient at baseline and 6 years after. Notice 
the significant diffuse spinal cord volume loss in all three planes of the patient’s images. 
 
Associations between SCV, TBV and T2LV across disease types 
Separate LMER analyses were performed to specifically investigate the extent of association between SCV, 
TBV, T2LV in each MS disease type. In PPMS, only age was associated with SCV loss over time. Male sex 
had a trend to a higher SCV average. Neither TBV nor T2LV were significantly related to SCV. In RRMS 
and SPMS, only TBV was associated with the average SCV, but no factors were associated with SCV loss 
over time. T2LV did not have a significant effect on SCV. Analyses details are exhibited in Table 10. 
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Table 10. Comparison of SCV, TBV and T2LV between disease types. 
SCV= Spinal Cord Volume; SD=Standard Deviation; TBV= Total Brain Volume; T2LV= Brain T2 Lesion Volume; PPMS=Primary Progressive MS; 
RRMS=Relapsing Remitting MS; SPMS=Secondary Progressive MS; n.s.=not significant for any comparisons between PPMS, RRMS and SPMS; 
B=regression coefficient; R2m= marginal R-squared; R
2
c= conditional R-squared  
Analysis was performed with linear mixed effect models with a random intercept and slope. 
 
 
 
 
Variable SCV (mm3) TBV (cm3) T2LV (mm3) 
 Average Loss over time Average Loss over time Average 
Increase over 
time 
Age n.s. n.s. B=-3.59, p<0.01 B=-0.19, p<0.05 n.s. n.s. 
Sex (Males) B=200, p<0.05 n.s. B=-55.2, p<0.001 n.s. n.s. n.s. 
Disease Duration n.s. n.s. B=-3.61, p<0.05 
n.s. 
(p=0.056) 
B=564, p<0.001 n.s. 
Disease Type 
PPMS vs 
RRMS 
B=-258, p<0.05 B=-29.1, p<0.01 
n.s. n.s. n.s. n.s. 
PPMS vs 
SPMS 
n.s. 
n.s. 
(B=-21.5, p=0.066) 
RRMS vs 
SPMS 
n.s. n.s. 
 Final model : R2m=21%, R2c=99% Final model : R2m=36%, R2c=98% Final model : R2m=25%, R2c=100% 
 Spinal Cord Volume Quantification And Clinical Application In Multiple Sclerosis – C. Tsagkas 
 
92 
 
Table 11. Associations between MRI measures across disease types 
 
 
 
 
 
SCV= Spinal Cord Volume; SD=Standard Deviation; TBV= Total Brain Volume; T2LV= Brain T2 Lesion Volume; PPMS=Primary Progressive MS; 
RRMS=Relapsing Remitting MS; SPMS=Secondary Progressive MS; n.s.=not significant for any comparisons between PPMS, RRMS and SPMS; 
B=regression coefficient; R2m= marginal R-squared; R
2
c= conditional R-squared 
Analysis was performed with linear mixed effect models with a random intercept and slope.
Variable 
PPMS RRMS SPMS 
Average SCV 
SCV loss over 
time 
Average SCV 
SCV loss over 
time 
Average SCV 
SCV loss over 
time 
Age n.s. B=3.66, p<0.05 n.s. n.s. n.s. n.s. 
Sex n.s. (p=0.088) n.s. n.s. n.s. n.s. n.s. 
Disease Duration n.s. n.s. n.s. n.s. n.s. n.s. 
TBV (mm3) n.s. n.s. B=6 x 10-4, p<0.05 n.s. B=6 x 10-4, p<0.05 n.s. 
T2LV (mm3) n.s. n.s. n.s. n.s. n.s. n.s. 
 Final model : R2m=5%, R2c=99% Final model : R2m=4%, R2c=98% Final model : R2m=2%, R2c=99% 
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SCV changes and disability  
In the LMER analyses, TBV (B=-9x10-7, p<0.05) and SCV (B=-2x10-4, p<0.05) were significantly correlated 
with the average EDSS over 6 years, but not with the EDSS increase over time. Age (B=0.004, p<0.05), 
disease duration (B=0.01, p<0.01), and disease type (PPMS vs RRMS: B=0.46, p<0.001; PPMS vs SPMS: 
not significant; RRMS vs SPMS: B=0.42, p<0.001) were also associated with the average EDSS, but not with 
the EDSS increase over time. Gender and T2LV did not contribute to the explanation of the EDSS. The final 
model accounted for 93%, while fixed effects alone accounted for 51% of the EDSS variance. 
Regarding T25fwt, TBV and T2LV did not significantly correlate to the T25fwt results while SCV had a trend 
to correlate with the average T25fwt speed (p=0.077), but not with the deterioration in T25fwt over time. 
Disease duration (B=-0.004, p<0.01) and disease type (PPMS vs RRMS: B=-0.06, p<0.05; PPMS vs SPMS: 
not significant; RRMS vs SPMS: B=-0.06, p<0.001) had a significant effect on the average T25fwt of the 
whole cohort of MS patients. No factors were associated with a faster deterioration in T25fwt over time, 
although sex had a trend toward significance (p=0.066). The final model accounted for 94%, while fixed 
effects alone accounted for 34% of the T25fwt variance. 
Separate LMER analyses were performed to specifically investigate the extent of association between SCV, 
TBV, T2LV to clinical outcomes in each MS disease type. Numerical details are displayed in Table 14.  
In PPMS, SCV correlated with EDSS increase over time and had a trend toward significance with the average 
EDSS over 6 years. TBV and T2LV were not significantly associated with EDSS.  Disease duration also 
correlated significantly to EDSS increase over time. TBV and SCV correlated with average T25fwt, while 
TBV and T2LV, but not SCV, were associated with the T25fwt worsening over time 
In RRMS, while age, SCV and TBV were associated with the average EDSS, but not with the EDSS increase 
over time, T2LV did not have a significant effect on the EDSS. Further, in regard of the T25fwt only SCV 
and T2LV were correlated with the T25fwt worsening over time, but not with the average T25fwt. Age and 
disease duration were associated with the average T25fwt. 
In SPMS, SCV, TBV and T2LV were not associated with the EDSS. Only male sex was significantly 
associated with the average EDSS. No factors were significantly correlated with the T25fwt, although there 
was a trend for a correlation between the SCV and the T25fwt worsening over time.  
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Table 12. Associations between MRI measures and clinical outcomes across disease types. 
EDSS=Expanded Disability Status Scale; T25fwt=Timed 25-foot walk test; SCV= Spinal Cord Volume; SD=Standard Deviation; TBV= Total Brain Volume; 
T2LV= Brain T2 Lesion Volume; PPMS=Primary Progressive MS; RRMS=Relapsing Remitting MS; SPMS=Secondary Progressive MS; n.s.=not significant 
for any comparisons between PPMS, RRMS, SPMS; B=regression coefficient; R2m= marginal R-squared; R
2
c= conditional R-squared  
Analysis was performed with linear mixed effect models with a random intercept and slope. 
 
Variable 
PPMS RRMS SPMS 
Clinical 
Outcome Outcome’s Average 
Outcome’s 
Change Over 
Time 
Outcome‘s Average 
Outcome’s 
Change Over 
Time 
Outcome’s Average 
Outcome’s 
Change Over 
Time 
E
D
S
S
 
Age n.s. B=3.66, p<0.05 B=0.01, p<0.01 n.s. n.s. n.s. (p=0.054) 
Sex (Males) n.s. (p=0.088) n.s. n.s. n.s. B=0.23, p<0.05 n.s. 
Disease Duration n.s. B=-0.003, p<0.05 n.s. n.s. n.s. (p=0.088) n.s. 
TBV (mm3) n.s.  n.s. B=-10-6, p<0.05 n.s. n.s. n.s. 
SCV (mm3) n.s. (p=0.078) B=-8x10-5, p<0.01 B=-5 x 10-4, p<0.05 n.s. n.s. n.s. 
T2LV (mm3) n.s. n.s. n.s. n.s. n.s. n.s. 
 Final model : R2m=13%, R2c=89% Final model : R2m=36%, R2c=89% Final model : R2m=21%, R2c=93% 
T
2
5
fw
t 
Age n.s. n.s. B=-10-3, p<0.05 n.s. n.s. n.s. 
Sex (Males) n.s. n.s. B=-0.003, p<0.05 n.s. n.s. n.s. 
Disease Duration n.s. n.s. n.s. n.s. n.s. n.s. 
TBV (mm3) B=7x10-7, p<0.01 B=-2x10-8 n.s. n.s. n.s. n.s.  
SCV (mm3) B=9x10-5, p<0.05 n.s. n.s. B=10-5, p<0.05 n.s. n.s. (p=0.055) 
T2LV (mm3) n.s. B=8x10-7, p<0.05 n.s. B=-5 x 10-7, p<0.05 n.s. n.s. 
 Final model : R2m=63%, R2c=94% Final model : R2m=41%, R2c=85% Final model : R2m=8%, R2c=96% 
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Discussion 
The present study investigated the upper cervical cord volume in a group of primary progressive MS patients 
in comparison to age-, sex- and disease duration-matched relapse-onset patients over a follow-up period of 6 
years. Our work demonstrated a marked and accelerated loss of SCV in PPMS compared to relapse-onset MS, 
pointing out a notable characteristic difference of this patient group. PPMS patients clearly showed a 
preferential loss of SC over brain volume and interestingly, SCV was the only measure correlating with the 
disability progression over time as measured by the EDSS in this patient group. These study results give 
important insight on the role of SC atrophy in PPMS. The long follow-up period with annual measurements 
and the well-matched disease groups in our study are especially valuable in expanding to the existing literature 
of partially controversial results regarding the dominant role of SC atrophy as a distinctive feature between 
MS disease types 44,45,97,140,143. 
On average, PPMS patients were found to have significantly reduced SC volumes compared to RRMS, as 
suggested by previous studies focusing on SC cross-sectional area 44,45,140. Moreover PPMS SCV declined 
significantly faster over the years compared to RRMS as well as by trend when compared with SPMS. To our 
knowledge, this is the first longer-term follow-up study demonstrating such a striking between-group 
difference of SCV loss over time 44,136. Furthermore, both average TBV or T2LV and their decline over time 
did not differ between groups and thus potentially underlining the significance of the observed increased SCV 
loss in PPMS.  
Interestingly, while in PPMS SCV and TBV seemed to be widely independent both in terms of average volume 
and volume loss over time (with preferential loss in SC), atrophy in relapse-onset patients seems to be in part 
a global process with a coherent impact on both the brain and the SC. This is supported by Ingle and colleagues 
finding no correlation between brain and spinal cord cross-sectional atrophy in a group of PPMS patients 136.  
The latter findings lead to an ongoing discussion in the field hypothesizing different underlying 
pathomechanisms in PPMS compared to relapse-onset MS and supporting the PPMS may represent a separate 
clinical entity 141. In PPMS neuronal injury has been reported to predominantly affect motor related brain 
structures, while in SPMS and RRMS a more widespread pattern was shown 145. Even from a clinical 
perspective, PPMS patients rather show motor-related than visual or sensory disturbances 140,146. Based on 
that, it is possible that there is a selective kind of neuronal damage on the level of the cord, explaining early 
neurodegeneration and diffuse pathology of the SC from the very onset of PPMS and continuous throughout 
the course of the disease 5,44,45,95,118,133–143. This pathology is then being depicted as spinal cord volume loss in 
MR images. Furthermore, a secondary axonal and neuronal loss in the SC through Wallerian degeneration of 
the projections of motor control areas is possible. This focal volume loss in the brain may be undetectable in 
measurements such as TBV, but highly evident in the SC, where the corticospinal tract and motor neurons 
take up a significant percentage of the cross-section. This would also be in line with our results providing 
independent information of brain versus spinal MRI atrophy measurements both cross-sectionally and 
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longitudinally. Last, obviously also a combination of both pathomechanisms, leading to cumulative volume 
loss in the cord, is also possible.  
Independent of the disease type SCV contributed significantly in the explanation of clinical disability, even 
after the introduction of TBV into the model, underlining the cords significance and prognostic capabilities 
discussed in the literature 5,44,45,77,134. When analysing each individual disease type separately, only PPMS 
patients showed a strong relation to disease progression. At the same time TBV and T2LV were not relevant 
contributors to the explanation of the EDSS and disease progression. This confirms previous results from 
cross-sectional studies and one longitudinal study of PPMS patients 95,136–139,143, as well as qualitative MRI 
studies showing the importance of SC pathology beyond brain metrics in the explanation of PPMS disability 
118,142,147. In contrast to PPMS, in RRMS TBV and T2LV seemed to play a bigger role in the explanation of 
clinical outcomes. However, even in RRMS SCV was a strong predictor of physical disability, measured both 
as EDSS and T25fwt. Concerning SPMS patients in our study no MRI factors had a significant effect on 
clinical outcomes. This might be explained by the relatively small number of SPMS patients, in combination 
with the limitation of clinical scores catching underlying clinical progression, especially in such highly 
disabled patients as the SPMS.   
The development of SC related physical disability in our group of PPMS patients in parallel to preferential 
SCV loss as compared to other MS-subtypes, emphasizes the inclusion of SCV measurements not only as a 
marker in clinical trials for emerging therapeutic agents, but also in the clinical routine in order to optimise 
individualised medicine in this patient group. SCV metrics may be the answer to the unmet need for reliable 
disease markers in PPMS. In a recent successful clinical trial investigating the therapeutic effect of 
Ocrelizumab compared to placebo in PPMS 148, a difference of 17.5% reduction in brain atrophy was evident 
in the treatment group. Using this effect as a meaningful atrophy reduction, our study demonstrated rather 
achievable numbers of patients per arm needed (94 patients for 1-year, 59 patients for 2-year follow up time; 
analysis not shown here) to reach such therapeutic effects in the SC, even with a fairly low size effect at a 
considerably high power (95%) and 5% significance. Cawley et al. 143 reported a minimum sample size of 57 
per arm aiming to detect a 50% reduction in percentage change in SC cross-sectional area in PPMS at 80% 
power and 5% significance in a 1-year neuroprotective clinical trial, whereas based on our results a minimum 
sample size of 7 per arm is needed to demonstrate the same effect. Although this finding may reflect a higher 
sensitivity of our method, the interpretation of these results requires caution because of the small sample size 
in both studies. However, with several agents currently being under investigation in phase II and III clinical 
trials in PPMS 149, our work suggests that SCV loss should be included as valuable outcome, being able to 
display even a small but clinically relevant therapeutic effect requiring a relatively low sample size. Utilizing 
our pipeline, this should be feasible by measuring SCV within brain scans, which are already included in most 
clinical trials.  
Few limitations have to be considered when interpreting our results. First, the small sample size of each 
individual MS subgroup and especially of PPMS requires caution when evaluating the findings, since it may 
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have affected our ability to reveal correlations between the MRI variables and clinical data. The propensity 
score matching allowed us to analyse the data of the small number of PPMS patients in comparison to the 
more frequently occurring relapsing-remitting and secondary progressive disease types. We believe that we 
could reduce imbalance between disease subgroups produced by time- and disease-related phenomena in CNS 
structures by using this matching strategy. Further, the strong correlation of SC volume and clinical disability 
despite the small number of PPMS patients as well as the long follow-up time of our cohort makes us believe 
that the data may nevertheless be representative for this disease type.  
Furthermore, the current retrospective study aimed to analyse follow-up data of a selected group of patients 
with MS. A loss of follow-up data over time cannot be excluded resulting in a potential bias related to the 
incomplete follow-up, although the proportion of MS patients with different disease types seems stable over 
6 years. Moreover, there was no available sample of healthy controls recruited in this study, making a 
distinction between MS-related SC atrophy and any SCV decrease due to normal aging impossible. However, 
according to previous studies age-dependent SCV loss in the normal population seems to be significantly 
lower, suggesting that the observed loss of SCV over time could be interpreted as a disease related effect 103. 
Unfortunately, to our knowledge there is no longitudinal study investigating the effect of age on SCV loss in 
healthy controls. Despite the advantages of e.g. shorter acquisition times and reduction of scanning costs, 
using brain scans for SCV evaluation may be hampered by geometrical distortion and/or reduced signal 
intensity at the edge of the field of view potentially influencing segmentation quality of the cervical cord 150. 
To avoid such interference we evaluated the SCV well beyond the edge of the FOV which should grant robust 
measures. However, studies actually comparing brain versus dedicated spinal cord images and segmentation 
outcome should be performed to address this issue. Another disadvantage of brain scans is the insufficient 
grey/white-matter segregation within the cord making SC grey matter atrophy estimations impossible. Finally, 
the MR-protocol of our study did not include a T2w sequence covering the area of volume measurement over 
all time points analysed here and therefore the effect of SC lesion volume was not taken into account.  
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4. Discussion and Outlook 
 
4.1. Spinal Cord Volume Quantification 
The SC is an area of great importance due to its critical role for locomotion und MRI of the SC is a valuable 
part of the diagnostic work-up in neurological disorders. MRI-based techniques to study SC abnormalities are 
not as well developed as for the brain. Currently, mainly MRI signal intensity changes within the SC are 
evaluated in the clinical management of disorders of the central nervous system in order to identify focal 
intramedullar pathology in terms of a qualitative assessment. However, cross-sectional or longitudinal 
quantitative measurements of SC volume deliver additional valuable information. In the past, SC atrophy was 
usually determined by assessing the cross-sectional area of the cervical cord, usually at the C2/C3 level, which 
has been shown to correlate with clinical measures, although reproducibility was limited and dependent on 
data quality as well as repositioning 27,40,41. Moreover, most of the proposed approaches focused on cervical 
and mid thoracic levels of the SC 27–34,36–39,42–46. Thus, disorders affecting predominantly the lumbar level of 
the SC, such as hereditary spastic paraplegia cannot be studied with the available quantification methods. In 
disorders affecting the entire SC it is currently poorly understood, if all SC segments are equally involved. 
Furthermore, segmentation of the SC into GM and WM with quantification of these two SC compartments in 
an automated fashion has only recently become possible 47–50. This task, however, remains challenging as 
state-of-the-art MR sequences so far only achieve an in-slice resolution of around 0.5 mm (considering the 
very small dimensions of the SC GM) while maintaining a good signal-to-noise ratio (SNR) and an acceptable 
acquisition time. This resolution is barely enough to visualize the SC’s butterfly-shaped GM structure. Taking 
into account, that mean SC volume changes in disorders such as MS range between 0.5-2.2% per year, it 
becomes apparent that new accurate and reproducible method for the development of such a biomarker. A fast 
and reliable SC GM quantification methods would allow to study this important structure in larger patient 
populations as well as to reveal the extent to which the SC GM can predict future outcomes for chronic diseases 
such as MS. 
This thesis presents clinical validation for the quantification of the lumbar SC using the Cordial software as 
an important application addition beyond the cervical SC. This is the first study validating the accuracy and 
precision of volumetric measurements of the lumbar SC calculated in a semi-automatic fashion and thus 
delivering a tool for fast and reliable lumbar SC volumetry in clinical settings. One of the most important 
advantages of the proposed method is that it relies on natural landmarks on the SC itself and in this way 
bypasses reproducibility obstacles related to the physiologic motion of the SC, which is greater in the lumbar 
region. The method demonstrated highly reproducible results within the lumbar region and therefore a high 
potential for application of this metric in longitudinal studies or clinical trials. Despite the fact that many 
neurological disorders affecting the lumbar SC were till recently considered incurable, the first therapeutic 
strategies against disorders such as spinal muscular atrophy showed impressive efficacy 151. This, however, 
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creates the need of accurate spinal cord markers to monitor the therapeutic effect over long periods of time. 
Thus, our work may provide a reproducible surrogate of neuronal injury (or integrity) in this part of the CNS.  
Further, the application of Cordial to a large set of long-term brain MRI follow up data of a heterogeneous 
group of MS patients was performed for the first time. It proved to be feasible within a reasonable time frame 
and gave important insight into the understanding of the disease. Notably, it also showed that the quantification 
of SC volume is applicable in a clinical setting using routine brain –and not SC- MRI sequences, acquired on 
an “older generation” MRI scanner (1.5T). This emphasizes the broad applicability of the proposed marker 
with minimum requirements or additional financial burden for MS-patients and physicians as well as clinical 
trials for new therapeutic agents. It also bypasses some financial and time restrictions resulting from 
requirements of an extra MRI of the SC, which hampered such studies for decades. 
Moreover, this thesis proposes a pipeline for the quantification of cervical SC GM and WM. This is one of 
the first approaches to visualize and quantify SC compartments in a feasible MR-acquisition time without any 
user-interface interaction. Our work utilized a novel MR-sequence (averaged magnetization inversion 
recovery acquisitions) with submillimeter in plane resolution (0.67 x 0.67mm2), which offers a surprisingly 
high contrast between GM and WM as well as between WM and CSF, together with a newly proposed 
variational segmentation algorithm with a shape prior modified for 3D data with a slice similarity prior 21,152. 
This pipeline was able to demonstrate a highly accurate and reproducible SC GM and WM segmentation. This 
approach will allow studying the relation of different SC volume compartments to SC and brain lesions, 
determine the degree and relevance of white versus grey matter loss in the SC, depict key areas of spinal cord 
involvement and to relate spinal cord changes to other advanced (brain and spinal cord) MRI measures 
longitudinally in MS and other neurological disorders. Since image processing time of our fully automatic 
method is negligible it seems promising not only for the application in large datasets in research settings but 
also in clinical routine, providing SC GM and WM measurements effortlessly.
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4.2. Spinal Cord Volume Loss in Multiple Sclerosis 
MS is an inflammatory-demyelinating disease of the central nervous system and continues to be a major cause 
of disability among young individuals leading to major health and socioeconomic disadvantages. 
Neurodegeneration seems to be the key driver for the accrual of physical and neuropsychological disability 
and atrophy is one of the hallmarks of neurodegeneration in MS. SC atrophy in MS –a measure of 
neurodegeneration- has previously been reported mainly in cross‐sectional studies 44,45,91–93. However, 
previous approaches have been hampered by the relatively low‐resolution and contrast of the acquired MR 
images, long measurement times, artifacts as well as the low reproducibility of the segmentation techniques 3. 
This has led to a lack in longitudinal data concerning SC atrophy in MS and consequently a gap in the 
clinicians’ understanding of the disease. Moreover, the potential of SC atrophy as a disease marker over long 
periods of time was unknown. 
The work presented in this thesis demonstrates a detailed investigation of SC atrophy across all MS subgroups 
over a fairly long follow-up time using brain MR-images. We examined the upper cervical SC volume, which 
anatomically contains all efferent and afferent fibers from and to the brain as well as the SC GM, and offers 
the best possible reproducibility of volumetric SC measurements. This is the first longer-term study of SC 
volume loss in a rather large dataset of MS patients including all disease phenotypes as well as multiple clinical 
and MRI metrics beyond SC volume. We were able to investigate in depth the clinical significance of SC 
volume loss and explore temporal features of the SC volume over the course of six years and in association 
with clinical and demographic characteristics of MS patients.  
In contrast to former studies suggesting a faster atrophy in the SC than in the brain, our study showed 
comparable SC atrophy rates in RRMS and SPMS with the reported brain atrophy rate in MS, which ranges 
between 0.5-1.0% per year. SC volume was shown to be particularly accelerated in the group of PPMS patients 
compared to relapse onset MS, while being the only MR metric associated with disability progression. In 
contrast brain volume loss in PPMS was similar to relapse onset MS. This shows that the SC is a predilection 
spot in PPMS and is a strong marker of clinical worsening. In contrast to previous studies, SPMS and RRMS 
patients did not differ in terms of SC atrophy rate, emphasizing on the similarities rather than the differences 
between those two disease subtypes. Interestingly, SC volume loss over time was not correlated with brain 
volumetric metrics, which suggests that atrophy progression is an independent process in the two CNS regions. 
In RRMS, SC volume loss was also partly related to the number of clinical relapses, which suggest a weak 
relationship with acute focal inflammatory events. 
SC proved to be a strong predictor of physical disability and disease progression, indicating that it may be a 
suitable marker for monitoring disease activity and severity in all disease types and especially in progressive 
MS (both SPMS and PPMS). Despite the fact that RRMS and SPMS had similar SC atrophy rates, in SPMS 
clinical outcomes correlated much stronger compared to RRMS. This implies that the key driver for clinical 
progression is not the same in the two groups. Indeed, recent studies point to an early thalamic involvement 
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in MS, which correlates highly with clinical outcomes 153. It seems that -for unknown reasons- SC pathology 
is of greater importance in later stages of the disease. SC volume also proved to be the only MRI metric to 
strongly explain the clinical progression over time as opposed to brain atrophy and lesion measures for all MS 
patients, which are currently commonly used in clinical trials. These results open a new chapter in the field of 
MRI-research in MS showing the importance of SC evaluation in these patients underlining not the need to 
include assessment of SC MRI atrophy metrics in the management of MS patients in the clinic. It also provides 
new insights about the mechanisms driving physical disability in different MS groups indicating that SC 
should be included in future clinical trials, especially in progressive MS. Apart from the issues answered, this 
work gave rise to many questions, namely concerning the pathophysiologic mechanisms leading to the 
observed between-group differences both in terms of SC atrophy rates and correlation strength between SC 
volume loss and clinical outcomes.  
In view of the results, SC volume metrics may be the answer to the unmet need for reliable disease markers 
in MS, especially in progressive MS. In a recent successful clinical trial investigating the therapeutic effect of 
Ocrelizumab compared to placebo in PPMS, a difference of 17.5% reduction in brain atrophy was evident in 
the treatment group 148. Using this effect as a meaningful atrophy reduction, our study demonstrated rather 
achievable numbers of patients per arm needed (94 patients for 1-year, 59 patients for 2-year follow up time; 
analysis not shown here) to reach such therapeutic effects in the SC, even with a fairly low size effect at a 
considerably high power (95%) and 5% significance. Cawley et al. 143 reported a minimum sample size of 57 
per arm aiming to detect a 50% reduction in percentage change in SC cross-sectional area in PPMS at 80% 
power and 5% significance in a 1-year neuroprotective clinical trial, whereas based on our results a minimum 
sample size of 7 per arm is needed to demonstrate the same effect. However, with several agents currently 
being under investigation in phase II and III clinical trials in PPMS, our work suggests that SCV loss should 
be included as valuable outcome, being able to display even a small but clinically relevant therapeutic effect 
requiring a relatively low sample size. Utilizing our pipeline, this should be feasible by measuring SCV within 
brain scans, which are already included in most clinical trials. 
In addition to the – proof of principle – application of these techniques in MS, the same imaging and post‐
processing strategies should be feasible also in other disorders affecting the SC including traumatic SC 
injuries, and degenerative SC disorders provided that similar quality 3D MRI data is available.
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4.3. Outlook and Future Research 
 
4.3.1. Lumbar Spinal Cord Segmentation 
Spinal Muscular Atrophy (SMA) is a neuromuscular genetic disease 154,155 characterized by a progressive loss 
of anterior horn motor neurons in the spinal cord and subsequent system‐wide muscle atrophy followed by 
progressive weakness and disability due to mobility impairment, respiratory, gastrointestinal, and functional 
complications 156. SMA is one of the most devastating neurological diseases in childhood and is the number 
one cause of death related to genetic dysfunction in children. 
Recent advances in understanding SMA etiopathogenesis prompted emergence of promising therapeutic 
strategies resulting in a number of successful clinical trials being performed worldwide 151,157. Further, 
longitudinal progression is typically slow and difficult to detect especially in milder forms of SMA. Therefore, 
in the view of recent developments in this field new meaning to patient monitoring was given in this rare 
disease with a wide phenotypic spectrum, creating the need for reliable biomarkers capable of reliably 
assessing disease progression and potential treatment effects.  
Translating our results from “Manuscript 1”, we intend to implement our method in a small cohort of 19 
untreated spinal muscular atrophy patients and matched healthy volunteers described in a previous study 158, 
in order to study lumbar SC atrophy compared to healthy controls in vivo. This cohort was observed for 54 
weeks, so that we aim to observe the SC volume changes in this time period and provide a measure of SC 
atrophy progression for future assessments. We also intend to investigate the correlation of those 
measurements with clinical outcomes and clinical progression over time. 
 
4.3.2. Spinal Cord Grey Matter Segmentation 
The SC GM was investigated in two recent previous cross-sectional studies using manual delineations of the 
butterfly-shaped GM. Schlaeger and colleagues observed evidence of GM atrophy of the cervical and thoracic 
SC compared to healthy controls 95,97. These studies also demonstrated marked GM atrophy in progressive 
MS subtypes compared to RRMS 95,97. More importantly, SC GM atrophy was found to be the most significant 
correlate of clinical disability over brain metrics such as GM and WM 95,97. However, more studies are needed 
to validate these results. Furthermore, the application and validation of automatic computer-based methods 
for SC GM segmentation is highly needed before further implementation in clinical routine. Finally, the 
changes of SC GM areas and/or volumes over time has never been investigated so far. 
Translating our results from “Manuscript 2”, our goal is to study a new cohort of MS patients cross-sectionally 
using the developed pipeline. At present more than 80 patients have been scanned at baseline and follow up 
evaluations (after one year) and first data analysis are still ongoing. We aim to study the suitability of the 
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developed methods to determine longitudinal changes of the SC compartments in MS and provide brand new 
insights with regard to this promising biomarker cross-sectionally and longitudinally. We also plan to study 
the relative contribution of SC metrics (GM and WM, lesions) to physical disability in relation to brain metrics 
(T2 lesion load, normalized brain volume, volume of GM versus WM). In view of recent studies identifying 
a MS patient group with absent brain WM demyelinating plaques and pronounced lesion load in the brain GM 
and the SC159, we intend to search for patients of this possibly newly discovered disease subtype in our cohort. 
 
4.3.3. Future Volumetric Studies in Multiple Sclerosis 
As a continuation of the presented work usign a large preexisting longitudinal dataset, we intent to also analyze 
other CNS structures such as the brain deep GM, the cerebellum and cortical thickness in this cohort. With 
regard to the SC, we plan to study atrophy progression in an even larger cohort of over 1000 patients observed 
longitudinally with the purpose of further examining differences between groups MS patients (e.g. RRMS and 
SPMS, early versus late stages of MS etc.).  
The standardized definitions of clinical courses of MS (RRMS, PPMS, and SPMS) were proposed in 1996 
and have been used in clinical routine ever since 160. However, these definitions are purely descriptive and do 
not provide information about the underlying pathophysiology of the disease. Thus, a classification based on 
specific pathomechanisms is still a much wanted unmet need and would be crucial for the effective selection 
of disease-modifying treatments 161. Thus, we intend to investigate the potential of MRI atrophy measurements 
(including the SC) to objectively classify MS patients with the intention to contribute to individualized medical 
decision-making in this disorder in the future.
 Spinal Cord Volume Quantification And Clinical Application In Multiple Sclerosis – C. Tsagkas 
 
105 
 
5. Contributions by the PhD student 
During my PhD, I had the opportunity to contribute to the planning and conduct of several research projects 
and finally was also able to explore my own research ideas. Through the courses I followed in the University 
of Basel and learning from my co-workers and supervisors, I had the opportunity to acquire a number of skills 
that will be essential for future research work. 
Performance of the image post-processing within the aforementioned projects helped me to expand my 
knowledge of SC anatomy and pathology and I became an experienced reader of conventional and non-
conventional SC MR-imaging. I further deepened my statistical skills within advanced courses of the 
University of Basel including the application of the R statistical software. This enabled me to conduct all 
statistical analyses of the aforementioned projects with the support of our research group. It will further allow 
me to implement my own ideas at the level of data mining and analysis in the future. Drafts and revisions of 
all manuscripts as well as the ethics proposal for the ongoing clinical study were written by myself with the 
support and help of my co-workers and supervisors. I presented our work at several international conferences 
as oral and poster presentations (European Committee for Teaching and Research in Multiple Sclerosis, annual 
a la recherche sur la Sclérose en Plaques) and at the end of my PhD was invited to give a lecture on SC MRI 
in MS at an international congress (26th Annual Meeting of the European Charcot Foundation). The ongoing 
projects on SC GM changes as well as its preliminary work (Manuscript 2) allowed me to contribute to all 
aspects of the study design, recruitment and clinical and MRI examination of participants. I further supervised 
two master students within our ongoing projects.  
The work and my gained experience within my PhD thesis lead to several active collaborations on projects 
including SC atrophy as an outcome measure (SC atrophy in progressive MS receiving Biotin by Dr. N. 
Collongues – manuscript under preparation; SC volume in SMA vs healthy controls by Prof. Dr. med. D. 
Fischer – under analyses). Further I was involved in the SC segmentation within the scope of three 
investigator-initiated studies conducted at MIAC AG (TEMSO trial, and two investigator-initiated research 
cohorts). 
Finally, the close collaboration within our research group gave me the opportunity to broaden my horizon to 
other related MRI research on MS patients. I was part of a recently published work focusing on the damage 
of the lateral geniculate nucleus in MS (in press in Neurology), for which I segmented the optic nerves and 
chiasm and participated in the draft together with all other co-authors. I also conducted all statistical analysis 
and helped in writing and drafting a currently unpublished work (currently under revision) regarding atrophy 
of deep GM in MS, whereas I am currently preparing multiple other longitudinal volumetric studies of the 
same cohort focusing on other CNS structures and new aspects of this disease as a principal investigator.
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6. Conclusion and closing remarks 
The work presented in this thesis consists of two core features focusing on SC volume quantification: a 
methodological and a clinical application.  
Regarding method development, in “Manuscript 1” we engaged with the validation of the first method reliably 
and accurately quantifying the lumbar SC volume in a semi-automatic fashion. This method requires minimum 
user-software interaction and is therefore suitable for further studies examining the lumbar SC with cross-
sectional and longitudinal design even in large cohorts. “Manuscript 2” provides a new pipeline for 
quantification of SC and GM of the cervical cord. This method implemented the newly developed AMIRA 
MRI sequence and a novel fully automatic method providing accurate and reproducible measurements of the 
SC compartments with essentially no user-software interaction. Therefore, this method is suitable for the 
examination of the SC in disorders affecting the SC such as MS even in studies with large-scale and 
longitudinal setting. Both proposed methods could be implemented in clinical routine in order to provide 
information to the clinician that are not detectable or quantifiable with the naked eye. 
With regard to clinical application of SC volume quantification, this work delivered new exciting insights 
about SC volume loss in MS patients of all disease subtypes. “Manuscript 3” was the first long-term 
longitudinal study systematically examining SC volume loss in a large cohort of relapse-onset MS. Our study, 
observed a mean annual SC volume loss of about 0.4% in RRMS and 0.6% in SPMS, but –in contrast to 
previous cross-sectional and short-term longitudinal studies- no statistically significant between-group 
difference was observed. On the other side, “Manuscript 4” focused on a small PPMS population in our cohort 
and found an accelerated SC volume loss (mean annual atrophy rate about 2%), in contrast to whole brain 
volume changes, which were similar between PPMS and relapse-onset MS. This points to a preferential SC 
volume loss in PPMS. Our work verified, that SC volume is a reliable biomarker going hand in hand with 
clinical changes and being able to predict future outcomes, especially in progressive MS. Finally, we were 
able to show that SC volume would be able to show clinically meaningful therapeutic effect in clinical trial 
with a rather small sample size. Our studies were able to shed light to important new aspects of MS and showed 
that accurate and reliable SC volume measurements would have a major impact on disease- and treatment-
monitoring. We presented SC volume as a new promising biomarker, which can be implemented in the clinical 
setting in the management of MS.  
In conclusion, we are confident that we provided the research community with the necessary tools for reliable 
and time-efficient atrophy quantification in the spinal cord. We were also able to systematically follow SC 
volume loss over time and contributed to establishing this biomarker in MS. Our research in MS and SC 
volume quantification in general may ultimately have an impact on understanding and monitoring of other 
neurological disorders and improve patient management in the foreseeable future.  
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